TW472041B - Process for preparing 4-substituted-1H-indole-3-glyoxamides - Google Patents

Process for preparing 4-substituted-1H-indole-3-glyoxamides Download PDF

Info

Publication number
TW472041B
TW472041B TW088106024A TW88106024A TW472041B TW 472041 B TW472041 B TW 472041B TW 088106024 A TW088106024 A TW 088106024A TW 88106024 A TW88106024 A TW 88106024A TW 472041 B TW472041 B TW 472041B
Authority
TW
Taiwan
Prior art keywords
formula
compound
alkyl
patent application
scope
Prior art date
Application number
TW088106024A
Other languages
Chinese (zh)
Inventor
Benjamin Alan Anderson
Nancy Kay Harn
Richard Duane Miller
Edward Francis Plocharczyk
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of TW472041B publication Critical patent/TW472041B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A process for preparing 1H-indole-3-glyoxamides useful for inhibiting SPLA2 and novel intermediates useful in the preparation of such compounds. A process for preparing a compound of the formula I or a pharmaceutically acceptable salt or prodrug derivative thereof wherein: R1 is selected from the group consisting of C7-C20 alkyl; where; R10 is selected from the group consisting of halo, C1-C10 alkyl, C1-C10 alkoxy, -S-(C1-C10 alkyl) and halo(C1-C10)alkyl, and t is an integer from 0 to 5 both inclusive; R2 is selected from the group consisting of hydrogen, halo, C1-C3 alkyl, C3-C4 cycloalkyl, C3-C4 cycloalkenyl, -O-(C1-C2 alkyl), -S-(C1-C2 alkyl), aryl, aryloxy, and HET; R4 is selected from the group consisting of -CO2H, -SO3H, and -P(O)(OH)2 or salt or prodrug derivatives thereof; and R5 is selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, halo(C2-C6)alkyl, bromo, chloro, fluoro, iodo and aryl; which process comprises the steps of (a) halogenating a compound of formula X, where R8 is (C1-C6)alkyl, aryl or HET; with SO2Cl2 to form a compound of formula IX, (b) hydrolyzing and decarboxylating a compound of formula IX, to form a compound of formula VIII, (c) alkylating a compound of formula VII, with a compound of formula VIII, to form a compound of formula VI, (d) aminating and dehydrating a compound of formula VI, with an amine of the formula R1NH2 in the presence of a solvent that forms an azeotrope with water to form a compound of formula V, (e) oxidizing a compound of formula V, by heating with a base and a compound of the formula RSOX where R is -(C1-C6)alkyl, or aryl or substituted aryl and X is -(C1-C6)alkoxy, halo or -OCO2(C1-C6)alkyl to form a compound of formula IV, (f) alkylating a compound of the formula IV, with an alkylating agent of the formula XCH2R4a where X is a leaving group and R4a is -CO2R4b, -SO3R4b, -P(O)(OR4b)2, or -P(O)(OR4b)H, where R4b is an acid protecting group, to form a compound of formula III, (g) reacting a compound of formula III, with oxalyl chloride and ammonia to form a compound of formula II, (h) optionally hydrolyzing a compound of formula II, to form a compound of formula I; and (I) optionally salifying a compound of formula I.

Description

472041 A7 B7 五、發明說明(1 ) 本發明係有關製備某些1H-W哚-3-乙二醯胺之方法,該化 合物適用於抑制如:敗血性休克之病症中sPLA2調節之脂肪 酉父釋出’並有關適用於製備此等化合物之中間物。 已知某些1H-吲嗓-3 -乙二醯胺爲哺乳動物spla2<強力且 具選擇性之抑制劑,適用於治療疾病如:敗血性休克、成 人呼吸困難症候群、胰炎、創傷、支氣管氣喘、過敏性鼻 炎、類風濕關節炎、及sPLA:謗發之相關疾病。例如:Ep〇 公告案No. 06751 10揭示此等化合物。 許多不同專利案及公告案説明使用4 _羥基叫哚中間物製 備此等化合物之方法。 M.朱利亞(Marc Julia)、J.伊格儉(Jean Ig〇len)及Η .伊格偷 (Hanne Igolen)述於 Bull. Soc. chim. France,1962, ρρ. ι〇60_ 1068 之文章"Recherches en serie indolique. VI sur tryptamines substituees1'说明某些4丨嗓_3_乙二酿胺及其轉化成色胺酸衍 生物之方法。 E.維舍歐(Romeo)等人述於醫藥與實聲醫療期刊(The Journal of Pharmacology and Experimental Therapeutics, Vol. 262, No. 3,(pp. 971-978)中之文章,,2-芳基-3-4丨哚乙二醯胺 (FGIN-1): —種新型之粒線體DBI受體(MDR)之強力專一性 配位體(2-Aryl-3-Indoleglyoxylamides (FGIN-1): A New472041 A7 B7 V. Description of the invention (1) The present invention relates to a method for preparing certain 1H-W indole-3-ethylenediamines. The compounds are suitable for inhibiting sPLA2-regulated fatty aunts in conditions such as septic shock. 'Release' and related intermediates suitable for use in the preparation of these compounds. Some 1H-indole-3-ethylenediamines are known to be mammalian spla2 < strong and selective inhibitors, suitable for treating diseases such as: septic shock, adult dyspnea syndrome, pancreatitis, trauma, bronchus Asthma, allergic rhinitis, rheumatoid arthritis, and sPLA: related diseases. For example: Ep〇 Publication No. 06751 10 discloses these compounds. Many different patents and publications describe methods for preparing these compounds using 4-hydroxy-indole intermediates. M. Julia (Marc Julia), J. Iggol (Jean Ig〇len) and Η. Iggol (Hanne Igolen) described in Bull. Soc. Chim. France, 1962, ρρ. Ι〇60_ 1068 article & quot Recherches en serie indolique. VI sur tryptamines substituees1 'illustrates some of the 4 丨 3_ ethylenediamine and its conversion to tryptophan derivatives. E. Romeo et al. Article in The Journal of Pharmacology and Experimental Therapeutics, Vol. 262, No. 3, (pp. 971-978), 2-Fang -3-4 丨 Indole ethylenediamine (FGIN-1): a new type of strong specific ligand for the mitochondrial DBI receptor (MDR) (2-Aryl-3-Indoleglyoxylamides (FGIN-1) : A New

Class of Potent and Specific Ligands for the Mitochondrial DBI Receptor (MDR))説明某些在哺乳動物中樞神經系統中 具有研究用途之2 -芳基-3-Μ丨嗓乙二醯胺。 化學摘要(Chemical Abstracts),Vol_ 67,1967,73028h 之 -4 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) • I I n —Ml III —i n n I In y— I n n (請先閱讀背面之注意事項本頁) . -I線_ 經濟部智慧財產局員工消費合作社印製 472041 A7 _ B7 五、發明說明(2 ) ” N -芊基吲嗓於質譜分析法中夕八列 11 π T (刀裂(Fragmentation 〇f N-benzylindoles in Mass Spectrometry)摘要説明各種經爷基取 代之苯酚,包括彼等於呻哚核心之3 ·位置上具有乙二醯胺 基團者。 美國專利案No. 3.,449,363説明於μ丨嗓核心之3 -位置具有乙 二醯胺基團之三氟甲基吲哚。 美國專利案No. 3,35 1,630説明α _取代之3 _吲哚基乙酸化 合物及此化合物與其乙二酿胺中間物之製法。 美國專利案No. 2,825,734說明使用3 _喇哚乙二醯胺中間物 如:1-苯乙基-2-乙基-6-瘦基-N-丙基-3-Θ丨哚乙二醯胺製備 3_(2-胺基-1 -#呈乙基)4丨哚之方法(參見實例3 〇 )。 美國專利案No. 4,3 97,850使用乙二醯胺啕哚作爲中間物製 備異哼唑基钊哚胺之方法。美國專利案Ν〇· 3,8〇1,594説明使 用3 -啕哚基乙二醯胺中間物製備之止痛劑。 Α.阿拉又(Aleman hy),E.F.阿丸瑞兹(ε. Fernandez Alvarez), 0_ Ν·羅培(0· Nieto Lopey)及 M.E.R.赫瑞茲(Herraez)述於”法 國化子會為(Bulletin De La Societe Chimique De France), 1974,12, pp. 2883-2888之文章”No. 565·-酵素抑制劑,XII.- (块丙胺基-2-乙基)-3-丨啤之製法"(N〇. 565· - Inhibiteurs d enzymes. XII. - Preparation de (propargylamino-2 ethyl)-3 indoles)説明啕哚核心之6員環上經氫取代之各種峭哚基_3-乙二醯胺。 G.柯倫茲(Gert Kollenz)與 C.拉貝·斯(Christa Labes)述於 Liebigs Ann. Chem., 1975,pp. ι 979. ι 933 之文章”卜二苯胺 -5- 本纸張尺度適用中國國家標準(CNS)A4規格(210 X 297公爱) -----3--*--ί — — —---· I I (請先閱讀背面之注咅本頁) ήπ· -線. 經濟部智慧財產局員工消費合作社印製 472041 A7 --------B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(3 ) 基_2,3-二氫-2,3-吡咯啶酮之喇哚轉化作用(Ind〇1_Umlagerung v〇n l-DiPhenylamin〇-2,3_dihydr〇_2,3_pyrr〇lid〇nen)説明苯基取 代之3 -乙二醯胺。 斗^這種方法均採j ..生,嚴基_吲嗓―中—.間〜物一。例如:美國專 利案No. 5,654,326 U_S(本文已以提及之方式完全併入本文 中)揭示一種製備4-取代_1H_诩哚_3_乙二醯胺衍生物之方 法,其包括由適當取代之4-甲氧吲哚(依RD.克拉克(Clark) 等人所述製備,Synthesis,1991, pp. 871-878,其内容已以 提及之方式併入本文中)與氫化鈉於二甲基甲醯胺中,於室 溫(20-25 °C)下反應’然後於周溫下使用芳甲基鹵化物處 理’產生之1 -芳曱基啕哚再使用三溴化硼於二氯甲烷中進 行0-去曱基化(T.Y.盛(Tsung-Ying Shem)與 C.A.溫特(Winter), Adv·立ru&㈣.,1977, 12, 176,其内容已以提及之方式併入 本文中),產生4 -羥基吲哚。羥基吲哚之烷化法係使用沈_ 溴燒酸酯於二甲基甲醯胺中使用氫化鈉作爲鹼完成。由α _ [(吲嗓-4-基)氧]疏酸酯先與草醯氣反應,然後與氨反應, 與氫氧化鈉於甲醇中水解後,即可轉化成乙二醯胺。 如上述製備4 -取代-1Η-吲哚-3-乙二醯胺衍生物之方法有 其用途。然而,此方法採用昂貴的試劑及對環境有害的有 機溶劑,產生含呋喃之副產物,而所需產物之收率卻相當 低。 另一種製備經適當取代之丙醯基乙酸酯之方法爲使用硫醯 氣鹵化。1¾化中間物經鹽酸處理後,與適當取代之環己二 酮反應,進行水解及脱除羧基化。以適當胺處理烷基化二 -6 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----Jir--*------裝--- (請先閱讀背面之注意事項本頁) 訂' .線. -1 - 472041 A7 ------- B7______- 五、發明說明(4 ) 綱’產生之4 -酮基啕哚於高沸點之極性烴溶劑(如:卡必醇) 中’於觸媒(如:Pd/C)之存在下回流,氧化成4-經基4丨哚, 其可再统化,如上述轉化成所需之乙二醯胺。 然而此方法限於需使用高溫氧化,且必須回收貴重之金屬 觸媒。 雖然上述製備4 -羥基吲哚中間物之方法令人滿意,但仍 需要更有效之轉形法。 本發明方法採用亞磺酸化步驟。 通常’亞績酸化反應採用氫化物鹼,該鹼可延缓引發放熱 反應及氣體釋放。在商業條件下不喜歡這種反應條件。 本案申請者已發現一種製備與延緩引發放熱反應無關並可 避免與氣體釋出有關之起泡現象之亞靖酸化中間物。 帕塔(Patai)在11亞磺酸 '酯及其衍生物之化學(丁匕 Chemistry of Sulfinic Acids, Esters and Their Derivatives) ^ 強威利乂子公司(John Wiley and Sons),1990, p. 11說明使用 各種活化劑合成亞磺酸酯及其鹽之方法。 本發明另一方面,申請者已發現一種商業上可用於製備亞 磺酸醋之方法,其收量較高,避免產集^^彳產顏』尤指砜 類),並使用價廉之試劑。 經濟部智慧財產局員工消費合作社印製 --------..------裝--- (請先閱讀背面之注意事項本頁) -線 本發明提供一種製備1HJ丨哚乙二醯胺之改良法。本發 ,之方法可使用價廉、容易取得、條件溫和之試劑具總收 量更佳,同一時避免產生味直副患物。此外,本方法可以使 吲哚上更多種取代基進行轉形作用。由下文及附綠申請專 利範圍中將更了解本發明其他目的、特色及優點。 円 本紙張尺度適财國國家標準(CNS)A4規格(210 X 297公愛) 04 72 4 A7 _B7 五、發明說明(5 ) 本發明提供一種製備式I化合物或其醫藥上可接受之鹽或 前藥衍生物之方法;Class of Potent and Specific Ligands for the Mitochondrial DBI Receptor (MDR) indicates that some 2-aryl-3-Methoxyethylenediamines have research use in the mammalian central nervous system. Chemical Abstracts, Vol_ 67, 1967, 73028h -4-This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) • II n —Ml III —inn I In y— I nn (Please read the caution page on the back first). -I line _ Printed by the Intellectual Property Bureau of the Ministry of Economic Affairs and Consumer Cooperatives 472041 A7 _ B7 V. Description of the invention (2) '' N-fluorenylindionate in mass spectrometry Eight columns of 11 π T (Fragmentation 〇f N-benzylindoles in Mass Spectrometry) abstract description of a variety of phenol substituted with a major group, including those who have an ethylenediamine group in the 3 · position. Patent No. 3., 449,363 describes trifluoromethylindole with ethylenediamine group at the 3-position of the core of the μ. US Patent No. 3,35 1,630 describes α_substituted 3 _Indolylacetic acid compound and a method for preparing the same and its ethylenediamine intermediate. US Patent No. 2,825,734 describes the use of 3 _indole ethylenediamine intermediates such as: 1-phenethyl-2-ethyl- 6-Leptyl-N-propyl-3-Θ 丨 Indole ethylenediamine prepared 3_ (2-amino-1-# is ethyl (4) Method of indole (see Example 3). US Patent No. 4,3 97,850 Method for preparing isoxazolylzolinamide using ethylenedioxamine indole as an intermediate. US Patent No. 3,3 80,1,594 illustrates analgesics prepared using 3-pyridylethylenediamine intermediates. A. Aleman hy, EF Fernandez Alvarez, 0_ Ν · 罗佩 (0 · Nieto Lopey) and MER Heraez in "Article of Bulletin De La Societe Chimique De France, 1974, 12, pp. 2883-2888" No. 565 · -Enzyme Inhibitors, XII.- (block propylamino-2-ethyl) -3- 丨 method for making beer " (No. 565 ·-Inhibiteurs d enzymes. XII.-Preparation de (propargylamino-2 ethyl) -3 indoles) A variety of hydrogenated pyridyl_3-ethylenediamines substituted on the 6-membered ring of the indole core. G. Kolenz and C. Christa Labes are described in Liebigs Ann. Chem. , 1975, pp. Ι 979. ι 933 Article “Diphenylaniline-5- This paper size applies to China National Standard (CNS) A4 specification (210 X 297 public love) ----- 3-*- ί — --- · II (Please read the note on the back of this page first) ήπ · -line. Printed by the Consumers ’Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 472041 A7 -------- B7 Employees’ Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs Printed 5. Description of the invention (3) Iridol conversion of (3) group_2,3-dihydro-2,3-pyrrolidone (Ind〇1_Umlagerung v〇n l-DiPhenylamin〇-2,3_dihydr〇_2,3_pyrr Oliden) illustrates phenyl substituted 3-ethylenediamine. Dou ^ This method adopts j .. raw, Yan Ji_induan—zhong-. For example: U.S. Patent No. 5,654,326 U_S, which is fully incorporated herein by reference, discloses a method for preparing a 4-substituted_1H_pyridine_3_ethylenediamine derivative, which includes Substituted 4-methoxyindole (prepared as described by RD. Clark et al., Synthesis, 1991, pp. 871-878, the contents of which are incorporated herein by reference) with sodium hydride in two In methylformamide, react at room temperature (20-25 ° C) and then treat with arylmethyl halide at ambient temperature to produce the 1-arylamidinium indole and then use boron tribromide 0-Demethylation in methyl chloride (Tsung-Ying Shem) and CA Winter (Adv. Li Ru & J., 1977, 12, 176) (Incorporated herein) to produce 4-hydroxyindole. The alkylation of hydroxyindole is accomplished by using sodium bromide in dimethylformamide and using sodium hydride as a base. From the α _ [(indox-4-yl) oxy] phosphanate, it is first reacted with grasshopper gas, then with ammonia, and after hydrolysis with sodium hydroxide in methanol, it can be converted into ethylenediamine. The method for preparing a 4-substituted-1fluorene-indole-3-ethylenediamine derivative as described above is useful. However, this method uses expensive reagents and organic solvents that are harmful to the environment to produce furan-containing by-products, and the yield of the desired product is quite low. Another method for the preparation of appropriately substituted propionyl acetate is the halogenation with thion gas. After treatment with hydrochloric acid, the hydration intermediate is reacted with appropriately substituted cyclohexanedione to undergo hydrolysis and decarboxylation. Treatment of alkylated di-6 with appropriate amine-This paper size is applicable to Chinese National Standard (CNS) A4 (210 X 297 mm) ---- Jir-* ------ pack --- (please Please read the note on the back page first) Order '. Wire. -1-472041 A7 ------- B7 ______- 5. Explanation of the invention (4) Outline of 4-ketoindole produced at high boiling point In a hydrocarbon solvent (such as carbitol), it is refluxed in the presence of a catalyst (such as Pd / C) to be oxidized to 4-transyl 4 丨 indole, which can be re-systematized and converted to the required ethyl alcohol as described above. Diamine. However, this method is limited to the use of high-temperature oxidation and must recover valuable metal catalysts. Although the above-mentioned method for preparing a 4-hydroxyindole intermediate is satisfactory, a more effective transformation method is still needed. The method of the present invention uses a sulfination step. Generally, the 'sub-acidification' reaction uses a hydride base, which delays the initiation of exothermic reactions and gas release. This reaction condition is not liked under commercial conditions. Applicants in this case have discovered a method for preparing an acidified intermediate that has nothing to do with delaying the initiation of an exothermic reaction and can avoid the blistering phenomenon associated with gas release. Pattai's Chemistry of Sulfinic Acids, Esters and Their Derivatives ^ John Wiley and Sons, 1990, p. 11 A method for synthesizing sulfinate and its salt using various activators is explained. In another aspect of the present invention, the applicant has found a method that can be used commercially for the preparation of sulfinate vinegar, which has a high yield and avoids the production of ^^ (produce color, especially sulfones), and uses cheap reagent . Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs --------..------ Packing --- (Please read the precautions on the back page first)-The present invention provides a preparation of 1HJ 丨Improved method of indole ethylenediamine. In this method, the reagent can be used with low cost, easy to obtain, and mild conditions, and the total yield is better. At the same time, it can avoid the occurrence of taste and side effects. In addition, this method can transform more kinds of substituents on indole. Other objects, features, and advantages of the present invention will be better understood from the following and the scope of patents attached to the green application.円 This paper is a national standard (CNS) A4 specification (210 X 297 public love) of the country of wealth 04 72 4 A7 _B7 V. Description of the invention (5) The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof or Methods of prodrug derivatives;

R1 其中: R1選自:C7-C2Q烷基; (請先閱讀背面之注意事項V®寫本頁) 裝R1 Among them: R1 is selected from: C7-C2Q alkyl; (Please read the precautions on the back first, write this page)

訂··. 經濟部智慧財產局員工消費合作社印製 其中: R10選自:鹵素,-CVCm烷基、-C「C10(烷氧基)、-SJCVCw 燒基)及鹵素(CrC10):i完基,且t爲0至5之整數; R2選自··氳、鹵素、-CrC3(烷基)、-C3-C4(環烷基)、-C3-C4(環 烯基)、-0(-01-(:2烷基)、-S(-CrC2)烷基、芳基、芳氧 基、及HET ; R4選自:-C02H、-S03H、及-P(0)(0H)2或其鹽或其藥衍生 -8- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 472041 A7 B7 五、發明說明(6 物;及 R5選自:氫,-(CrC6)烷基、-(CrC6)烷氧基、鹵素(cvc6) 烷氧基、鹵素(C2-C6)烷基、溴、氣、氟、碘及芳基; 該方法包括下列步驟: a) 由式X化合物 0 0 、cA^r2Order ··. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economy Among them: R10 is selected from: halogen, -CVCm alkyl, -C "C10 (alkoxy), -SJCVCw alkyl) and halogen (CrC10): i finished And t is an integer from 0 to 5; R2 is selected from the group consisting of 氲, halogen, -CrC3 (alkyl), -C3-C4 (cycloalkyl), -C3-C4 (cycloalkenyl), -0 ( -01-(: 2 alkyl), -S (-CrC2) alkyl, aryl, aryloxy, and HET; R4 is selected from: -C02H, -S03H, and -P (0) (0H) 2 or Its salt or its drug derivative -8- This paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 472041 A7 B7 V. Description of the invention (6 substances; and R5 is selected from: hydrogen,-(CrC6) Alkyl,-(CrC6) alkoxy, halogen (cvc6) alkoxy, halogen (C2-C6) alkyl, bromine, gas, fluorine, iodine and aryl; the method includes the following steps: a) by formula X Compound 0 0, cA ^ r2

X 其中R8爲(CVC6)烷基、芳基或HET ; 與S02Cl2i'化形成式IX化合物 (請先閱讀背面之注意事項寫本頁)X where R8 is (CVC6) alkyl, aryl or HET; with S02Cl2i 'to form a compound of formula IX (please read the precautions on the back to write this page)

0 Q0 Q

σ 丫 R C1 IX; b)由式IX化合物水解及脱除羧基σ γ R C1 IX; b) hydrolysis and removal of carboxyl group from compound of formula IX

0 Q0 Q

·〇· 丫 R C1· 〇 · Ya R C1

IX 經濟部智慧財產局員工消費合作社印製 形成式VIII化合物 c) 由式VII化合物 C1 〇IX Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs to form a compound of formula VIII c) From compound of formula VII C1.

VIII -9- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 472041 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(7 與式VIII化合物進行烷化 形成式VI化合物 d)由式VI化合物VIII -9- This paper size is in accordance with China National Standard (CNS) A4 (210 X 297 mm) 472041 A7 B7 Printed by the Consumer Cooperative of Intellectual Property Bureau of the Ministry of Economic Affairs 5. Description of the invention (7 Formed by alkylation with a compound of formula VIII Compound of formula VI d) from compound of formula VI

r5VC^0r5VC ^ 0

VII C1VII C1

VIII 1 n n 4*1 I - — -I vwd ·11 n I— I in n (請先閱讀背面之注意事項寫本頁) 〇VIII 1 n n 4 * 1 I-— -I vwd · 11 n I— I in n (Please read the precautions on the back first to write this page) 〇

R 〇R 〇

R VI. VI 與式RiNI^於可與水共沸之溶劑存在下,進行胺化及脱水, 形成式V化合物 〇 人 R~ 'V; 訂; -線. -10- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)R VI. VI and formula RiNI ^ are subjected to amination and dehydration in the presence of a solvent capable of azeotroping with water to form a compound of formula V. Human R ~ 'V; order; -line. -10- This paper size applies to China Standard (CNS) A4 specification (210 X 297 mm)

0H0H

472041 A7 B7 五、發明說明(8 ) e ) 由式V化合物472041 A7 B7 V. Description of the invention (8) e) From the compound of formula V

與鹼及式RSOX化合物加熱,其中R爲-(CrC6)烷基、芳基或 經取代芳基,且X爲-(CrC6:r^氧基、鹵素或-OCOJCVCJJ^ 基,氧化形成式IV化合物 IV; f) 由式IV化合物 m n n * n i nt n HI 1 * HI ^^1 (請先閱讀背面之注意事項寫本頁) 訂.:Heating with a base and a compound of formula RSOX, wherein R is-(CrC6) alkyl, aryl or substituted aryl, and X is-(CrC6: r ^ oxy, halogen or -OCOJCVCJJ ^ group, and oxidizes to form compound of formula IV IV; f) Ordered by the compound of formula IV, mnn * ni nt n HI 1 * HI ^^ 1 (please read the notes on the back to write this page) .:

0H0H

V I r! R 線_ 經濟部智慧財產局員工消費合作社印製 與式XCH2R44_fe化劑烷化,其中X爲脱離基,且尺“爲 -C02R4b、-S03R4b、-P(0)(0R4b)2、或-P(〇)(〇R4b)H,其中 R4b 爲酸保護基團,形成式III化合物VI r! R line _ Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs and alkylated with the formula XCH2R44_fe alkylating agent, where X is a radical and the ruler is -C02R4b, -S03R4b, -P (0) (0R4b) 2 Or -P (〇) (〇R4b) H, wherein R4b is an acid protecting group, forming a compound of formula III

OCH ROCH R

R III; 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 472041 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明( g)由式III化合物R III; This paper size is in accordance with Chinese National Standard (CNS) A4 (210 X 297 mm) 472041 A7 B7 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 5. Description of the invention (g) Compounds of formula III

RR

III 與草酸氣及氨反應,形成式11化合物III reacts with oxalic acid and ammonia to form a compound of formula 11

h) 可視需要水解式11化合物h) Hydrolyze the compound of formula 11 if necessary

RR

II 形成式I化合物;及 i) 可視需要由式I化合物成鹽。 本發明另一項具體實施例係提供一種製備式I化合物之方 法,其包括下列步驟·· a) 由式V化合物II forms a compound of formula I; and i) optionally forms a salt from a compound of formula I. Another embodiment of the present invention provides a method for preparing a compound of formula I, which comprises the following steps: a) From a compound of formula V

AA

N R 2N R 2

V ________ir n m n n I n I (請先閱讀背面之注意事項寫本頁) 訂- 線. -12- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)V ________ir n m n n I n I (Please read the notes on the back to write this page first) Order-line. -12- This paper size applies to China National Standard (CNS) A4 (210 X 297 mm)

0H0H

R 472041 A7 B7 五、發明說明(1〇 與鹼及式RSOX化合物加熱,其中R爲-(Crc6)烷基、芳基或 經取代芳基且X爲-(CrC6)烷氧基、鹵素或-(^(^(^-(^烷 基,氧化形成式IV化合物R 472041 A7 B7 V. Description of the invention (10) Heating with a base and a compound of formula RSOX, where R is-(Crc6) alkyl, aryl or substituted aryl and X is-(CrC6) alkoxy, halogen or- (^ (^ (^-(^ Alkyl, oxidized to form a compound of formula IV

0H IV; b ) 由式IV化合物OH IV; b) by a compound of formula IV

IV 與式X C H 2 R 4 a烷化劑烷化,其中X爲脱離基,且R 4 a爲 -C〇2R4b、-S03R4b、-P(〇)(〇R4b)2、或-P(〇)(〇R4b)H,其中 R4b 爲酸保護基團,形成式111化合物 .— 1 I -I I —-〆1 — 11 — 1 I - (請先閱讀背面之注意事項寫本頁) 訂: -線·IV is alkylated with an alkylating agent of formula XCH 2 R 4 a, where X is a leaving group, and R 4 a is -CO2R4b, -S03R4b, -P (〇) (〇R4b) 2, or -P (〇 ) (〇R4b) H, where R4b is an acid-protecting group, forming a compound of formula 111. — 1 I -II —- —1 — 11 — 1 I-(Please read the precautions on the back to write this page) Order:- line·

〇CH R R〇CH R R

R 經濟部智慧財產局員工消費合作社印製 III; c) 由式III化合物R Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs III; c) from compounds of formula III

III 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 472041 A7 B7 五、發明說明(11 ) 與草醯氯及氨反應,形成式11化合物III This paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 472041 A7 B7 V. Description of the invention (11) Reaction with grasshopper chlorine and ammonia to form the compound of formula 11

RR

R II; 及 d)可視需要水解式11化合物R II; and d) optionally hydrolyze the compound of formula 11

II 形成式I化合物;及 e )可視需要由式I化合物形成鹽。 本發明另一項具體實施例係提供一種製備式I化合物之方 法,其包括下列步驟: a)由式V化合物 〇 人 (請先閱讀背面之注意事項寫本頁) 經濟部智慧財產局員工消費合作社印*1衣II to form a compound of formula I; and e) optionally forming a salt from a compound of formula I. Another specific embodiment of the present invention is to provide a method for preparing a compound of formula I, which includes the following steps: a) from a compound of formula V (please read the notes on the back first to write this page) employee consumption of the Intellectual Property Bureau of the Ministry of Economic Affairs Cooperative print * 1 clothing

經鹼及式RSOX化合物處理,其中R爲-(CrC6)烷基、芳基、 或經取代芳基,且X爲-(CrC6)烷氧基、鹵素或-OCOJCVC^) 丈完基,氧化形成式V 1化合物 14- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 472041 A7 B7 五、發明說明(12 )Treated with a base and a compound of formula RSOX, where R is-(CrC6) alkyl, aryl, or substituted aryl, and X is-(CrC6) alkoxy, halogen, or -OCOJCVC ^), and is oxidized to form Compound 14 of Formula V 1- This paper size applies to Chinese National Standard (CNS) A4 (210 X 297 mm) 472041 A7 B7 V. Description of the invention (12)

S RS R

V RV R

-—I 加熱式V1成份,形成式IV化合物-—I Heating formula V1 to form compound of formula IV

OHOH

R IV,· ----1---h------裝--- (請先閱讀背面之注意事項寫本頁) b ) 由式IV化合物R IV, · ---- 1 --- h ------ pack --- (Please read the precautions on the back first to write this page) b) from the compound of formula IV

OHOH

RR

IVIV

經式XCH2R4a烷化劑烷化,其中X爲脱離基且1143爲-C〇2R 4b n 一、V - ·-"1口· -線· 經濟部智慧財產局員工消費合作社印製 S〇3R4b、-P(〇)(〇R4b)2、或-P(〇)(〇R4b)H,其中1145爲酸保護 基,形成式111化合物Alkylated via the formula XCH2R4a alkylating agent, where X is a leaving group and 1143 is -C〇2R 4b n I. V-·-" 1 mouth · -line · Printed by the Consumer Consumption Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. 3R4b, -P (〇) (〇R4b) 2, or -P (〇) (〇R4b) H, where 1145 is an acid protecting group to form a compound of formula 111

R c) 由式III化合物 -15- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 472041 A7 B7 五、發明說明(13 )R c) From the compound of formula III -15- This paper size is applicable to Chinese National Standard (CNS) A4 (210 X 297 mm) 472041 A7 B7 V. Description of the invention (13)

^ III 與草醯氣及氨反應,形成式π化合物^ III reacts with grass gas and ammonia to form a compound of formula π

II ;及 d) 可視需要水解式11化合物 I — I *i _ I I (請先閱讀背面之注意事項寫本頁) 訂··II; and d) if necessary, hydrolyze the compound of formula 11 I — I * i _ I I (please read the precautions on the back to write this page) Order ··

R 丨線_ 形成式I化合物;及 本發明並提供式V 1新穎中間物 經濟部智慧財產局員工消費合作社印製R 丨 line _ forms a compound of formula I; and the present invention provides a novel intermediate of formula V 1 printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs

S RS R

IV 2 R 本纸張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 472041 經濟部智慧財產局員工消費合作社印制取 A7 -—-------B7_____ ' —-----五、發明說明(14) —其中RhV與R5均如上述定義且RHC6成基、芳基或 經取代芳基。此等化合物適用於製備式〗化合物之方法。 本發明另一方面提供一種製備式RS〇x之方法,其中尺爲 -(CVC6)垸基、芳基或經取代芳基且又爲瓜夂)燒氧基;$ 包括以酸及如式-(CrC2)0:H之醇處理如下式化合物 〃、 0II RSOM 其中R爲-(CrC6)烷基、芳基或經取代芳基且河爲鹼金屬。 本發明化合物採用某些如下定義之名詞: 本文中#用之"烷基”一詞本身或作爲另—個取代基之— 部份時,除非另有定義,否則係指直鏈或分支鏈單^烴自 由基如:甲基、乙基、正丙基、異丙基、正丁基、第三丁 基、異丁基、第二丁基、第三丁基、正戊基、異戊基、新 戊基、庚基、己基、辛基、壬基'癸基、等等。 本文採用之”(crc10)烷氧基”一詞係指如:甲氧基、乙氧 基、正丙氧基'異丙氧基、正丁氧基、第三丁氧基、正戊 氧基、異戊氧基、新戊氧基、庚氧基、己氧基、辛氧美、 壬氧基、癸氧基,及類似基團,其利用氧原子附接分子其 餘部份。 A "(Cr C4)環淀基” 一詞包括環丙基及環丁基。 ” C r C4環烯基”一詞包括於1 -或2 _位置具有雙鍵之環丙烯 基或環丁烯基環。 "鹵素''一詞包括氟、氣、溴或琪。 π鹵素(Crci0)烷基” 一詞指(CVC^o)烷基經1至3個自原子 -17- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事寫本頁) :Γ. -*裝 . ί線· ,472041 A7 B7_________ 五、發明說明(15) 取代,利用烷基附接分子之其餘部份。,I鹵素(c 一詞包括"由素(c2-c找基"一詞。 丄基 ”鹵素(CrC6)烷氧基”—詞指經鹵素取代之烷氧基利用燒 氧基之氧附接分子之其餘部份。 ~ ”芳基π —詞指具有下列環結構特徵之基團··笨、戊搭缔 茚、莕、甘菊環、庚搭晞、菲、Ε、等等。芳基可视需要 經1至3個選自下列之取代基取代:(Ci_Cs)烷基(以曱基較 佳)、(C「C6)烷氧基或鹵素(以氟或氯較佳)。 ”芳氧基”一詞指利用氧連接基附接分子之其餘部份之芳 基。 - ’’脱離基”一詞指具有非共同電子對在親核性取代反應中 可與文質分離之取代基。”脱離基” 一詞包括商素、磺酸 根、乙酸根,等等。 HET-詞包括,比淀”比,井”密症、^井”比略”比唑”夫 喃、嘧吩、嘧唑、異噻唑、哼二唑、嘍二唑、咪唑、三唑 及四唑。雜塚可利用雜環中任何碳附接分子之其餘部份。 經濟部智慧財產局員工消費合作社印製 II ^ - I n 1 .Γ n I 1 n I I I (請先閲讀背面之注意事寫本頁) 線· 式I化合物之鹽爲本發明之另一方面。若本發明化合物具 有酸性官能基時,可形成比母化合物更具水溶性及生理上 更合適之各種鹽。代表性之醫藥上可接受之鹽包括(但不限 於)··鹼金屬及鹼土金屬鹽如··銼、鈉、鉀、鈣、鎂、銘、 等等之鹽。鹽類容易由該游離酸製備,其係由酸之溶液經 鹼處理或由酸經過離子交換樹脂處理。 醫藥上可接文之鹽之定義内包括:本發明化合物之相當無 毒性無機與有機鹼加成鹽,例如:衍生自具充份驗性之含 -18- 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐) 472041 A7 ------B7_____ 五、發明說明(16 ) 氮驗之銨、四級按及胺陽離子與本發明化合物形成之鹽(參 見例如· S.M.柏格(Berge)等人,"醫藥用鹽”(pharmaceut;[cai Salts),J· Phar. Sci.. 66: 1 -1 9( 1977))。 本文採用之”酸保護基”一詞如同合成有機化學常用者, 係如遠基團可以防止酸根參與分子上其他一些官能基進行 之反應,但若需要時可以脱除。此等基團已討論於T W.葛 林(Greene)之,,有機合成法之保護基團”(Pr〇tective Gr〇ups in Organic Synthesis),第5章,(紐約強威利父子公司(J〇nh Wiley and Sons,New York,1981) ’該文獻係以提及之方式 冗全併入笨文中。 酸保護基團實例包括酸根之酯或醯胺衍生物,如:甲基、 甲氧甲基、甲基硫甲基、四氫P比喃基、甲氧乙氧甲基、苄 氧甲基、苯芳基、乙基、2,2,2_三氣乙基、2_甲硫乙:、第 三丁基、環戊基、三苯甲基、對溴苄基、三甲矽烷基、 N,N-二甲基、吡咯啶基、六氫吡啶基或鄰硝基醯替苯胺。 較佳之酸保護基團爲甲基。 經濟部智慧財產局員工消費合作社印製 --------!-------裝--- (請先閱讀背面之注意事寫本頁) -線· 前藥係指本發明化合物之衍生物,其具有化學上或代謝上 可裂解之基團,且經由溶劑分解作用或於生理條件下而成 爲在活體内具有醫藥活性之本發明化合物。本發明化合物 之衍生物之酸及鹼衍生物型均具有活性,但酸衍生物型通 4 k供有利之洛解性、組織相容性、或於哺乳動物生物體 内延緩釋放之優點(參見Η ·本加得(Bundgard)之”藥物設計算^ (Design of prodrugs),pp. 7_9, 21_24,阿姆斯特丹艾斯威爾 公司(ElSevier,Amsterdam), 1985)。前藥包括酸衍生物, -19- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公髮) ' --~~. ,472041 A7 五、發明說明(17) 如:由酸性母化合物與合適醇反應製 仆人物盘人、S η, — 酉日 或由酸性母 '人… 應製成之醯胺。較佳前藥爲衍生自本於 明化合物上侧接酸性基團之簡單脂系黯類(例自心 酯、Γ旨、異丙酿、丁醋、第二丁酷、第三丁醋)或曰芳香 胺談基甲氧基。 土乳—乙-酉于酿胺及二乙 :情需要製備雙醋型前藥,如:(酿氧旬垸基醋 或((k氧故基)氧)燒基酯。 依本發明方法製備之較佳式丨化合物爲彼等其中: R1爲 (CH山.IV 2 R This paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 472041 Printed and printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 ---------- B7_____ '--- --- V. Description of the invention (14)-wherein RhV and R5 are as defined above and RHC6 is formed into a group, an aryl group or a substituted aryl group. These compounds are suitable for use in the preparation of compounds of formula. Another aspect of the present invention provides a method for preparing formula RS0x, wherein the ruler is-(CVC6) fluorenyl, aryl, or substituted aryl, and is also melamine); (CrC2) 0: H is treated with an alcohol of the formula 〃, 0II RSOM where R is-(CrC6) alkyl, aryl or substituted aryl and R is an alkali metal. The compounds of the present invention use certain terms as defined below: When used herein, the term "alkyl" or "as part of another substituent" refers to a straight or branched chain unless otherwise defined Monoalkyl hydrocarbon radicals such as: methyl, ethyl, n-propyl, isopropyl, n-butyl, third butyl, isobutyl, second butyl, third butyl, n-pentyl, isopentyl Group, neopentyl, heptyl, hexyl, octyl, nonyl'decyl, etc. The term "(crc10) alkoxy" as used herein refers to, for example: methoxy, ethoxy, n-propyl Oxy'isopropoxy, n-butoxy, tertiary butoxy, n-pentoxy, isopentyloxy, neopentyloxy, heptyloxy, hexyloxy, octyloxy, nonyloxy, Decyloxy, and similar groups, use an oxygen atom to attach the rest of the molecule. A " (Cr C4) cycloalkyl '' includes cyclopropyl and cyclobutyl. The term "C r C4 cycloalkenyl" includes a cyclopropenyl or cyclobutenyl ring having a double bond at the 1-or 2- position. The term " halogen " includes fluorine, gas, bromine, or chi. The term “π halogen (Crci0) alkyl” refers to (CVC ^ o) alkyl via 1 to 3 self-atoms-17- This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) (please first (Read the notes on the back and write this page): Γ.-* 装. Ί Thread, 472041 A7 B7_________ V. Description of the invention (15) Substitution, using an alkyl group to attach the rest of the molecule. I halogen (c Includes the term "from the base (c2-c)". The fluorenyl "halo (CrC6) alkoxy"-the term refers to a halogen-substituted alkoxy group using the oxygen of the alkoxy group to attach the rest of the molecule ~ "Aryl π — The word refers to a group having the following ring structure characteristics: · Ben, penta-indene, fluorene, chamomile ring, heptyl, phenanthrene, E, etc. The aryl group may be subjected to 1 to 3 as needed. (Ci_Cs) alkyl (preferably fluorenyl), (C "C6) alkoxy or halogen (preferably fluorine or chlorine). The term" aryloxy "refers to the use of An aryl group of the oxygen linker attaches to the rest of the molecule.-The term "leaving group" refers to a substituent having a non-common electron pair that can be separated from the substance in a nucleophilic substitution reaction. The term "leaving group" includes commercial elements, sulfonates, acetates, etc. The HET-words include, "Beyond" ratio, "Dense disease", "well" ratio, "Bizazole", furan, pyrimidine, pyrimidine Azole, isothiazole, humidiazole, oxadiazole, imidazole, triazole, and tetrazole. Zazuka can use any carbon in the heterocyclic ring to attach the rest of the molecule. Printed by the Consumer Cooperative of the Intellectual Property Bureau, Ministry of Economic Affairs II ^ -I n 1 .Γ n I 1 n III (please read the note on the back to write this page first). The salt of the compound of formula I is another aspect of the present invention. If the compound of the present invention has an acidic functional group, it can form Various salts that are more water-soluble and physiologically more suitable than the parent compound. Representative pharmaceutically acceptable salts include (but are not limited to) ... alkali metal and alkaline earth metal salts such as ... files, sodium, potassium, calcium, Salts of magnesium, ming, etc. Salts are easily prepared from the free acid, which is treated with a solution of an acid by alkali or by an acid with an ion exchange resin. The definition of a pharmaceutically acceptable salt includes: the present invention A fairly non-toxic inorganic and organic base addition salt of a compound, eg derived from Fully testable -18- This paper size applies to Chinese National Standard (CNS) A4 (210 χ 297 mm) 472041 A7 ------ B7_____ V. Description of the invention (16) Nitrogen test ammonium, four Grades and salts formed by amine cations and compounds of the present invention (see, eg, SM Berger et al., &Quot;pharmaceut; [cai Salts), J. Phar. Sci .. 66: 1- 1 9 (1977)). The term "acid protecting group" used in this paper is like that commonly used in synthetic organic chemistry. For example, a remote group can prevent acid radicals from participating in the reaction of other functional groups on the molecule, but can be removed if necessary. . These groups have been discussed in T. Greene, "Protective Grups in Organic Synthesis", Chapter 5, (Johnson & Sons, New York ( Jonh Wiley and Sons, New York, 1981) 'This document is incorporated by reference in a stupid way. Examples of acid protecting groups include acid esters or amidine derivatives, such as methyl, methoxy Methyl, methylthiomethyl, tetrahydropyranyl, methoxyethoxymethyl, benzyloxymethyl, phenylaryl, ethyl, 2,2,2-trifluoroethyl, 2-methylthio Ethyl: tertiary butyl, cyclopentyl, trityl, p-bromobenzyl, trimethylsilyl, N, N-dimethyl, pyrrolidinyl, hexahydropyridyl, or o-nitropyridinoline. The preferred acid-protecting group is methyl. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs --------! ------- pack --- (Please read the note on the back first (Page)-Line · Prodrug refers to the derivative of the compound of the present invention, which has a chemically or metabolically cleavable group, and has pharmacological activity in vivo through solvolysis or under physiological conditions The compounds of the present invention. The derivatives of the compounds of the present invention are active in both acid and base derivatives, but the acid derivatives can be used for favorable dissolution, histocompatibility, or delay in mammalian organisms. Advantages of release (see “Design of prodrugs” in Bundgard, pp. 7_9, 21_24, ElSevier, Amsterdam, 1985). Prodrugs include acids Derivatives, -19- This paper size is applicable to Chinese National Standard (CNS) A4 specifications (210 X 297 issued) '-~~., 472041 A7 V. Description of the invention (17) For example: the acidic parent compound and suitable alcohol Responsive characters Panren, S η, — the next day or the acidic mother's… should be made amidine. The preferred prodrugs are simple lipids derived from the acid compounds on the side of the compound (Eg Zixin ester, Γ purpose, isopropyl alcohol, butyl vinegar, second butyl vinegar, third butyl vinegar) or aryl aryl thiol methoxy group. It is necessary to prepare a diacetate-type prodrug, such as: (fermented oxenyl vinegar or ((k-oxyalkyl) oxy) oxy) alkyl esters. The compounds of the preferred formula prepared by the inventive method are among them: R1 is (CH.

— II--I.----— I-裝 — I (請先閱讀背面之注意事寫本頁) 經濟部智慧財產局員工消費合作社印製 其中(R10)t選自:商素、_Ci_Ci〇烷基、_c「Ci〇(烷氧基)、_s_ (CrC10)侯;基及!|素(Ci_Ci〇)烷基,且# 〇至$之整數; R2爲自素、環丙基、曱基、乙基、丙基、〇 -甲基或s_曱基; R4爲-C02H ;及 R5、R6 及 R7 爲 Η。 較佳式V 1化合物爲彼等其中: R爲芳基 其中R10選自:鹵素、_(Ci_C|〇)烷基、_(Ci_Ci〇)烷氧基、-S-(匸丨-<:10)烷基及鹵素((::丨_(^〇)烷基,且1爲〇至5之整數; R2選自:鹵素、環丙基、甲基、乙基、〇_甲基或S -甲基;且 R5爲 Η。 甚至更佳者爲式V1化合物中: -20- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 訂· -線· 472041 A7 B7 (CH,)— II--I .----— I- 装 — I (Please read the notes on the back to write this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs where (R10) t is selected from: Shangsu, _Ci_Ci 〇alkyl, _c "CiO (alkoxy), _s_ (CrC10) alkyl; and Ci! Ci (Ci_) alkyl, and an integer of # 0 to $; R2 is from prime, cyclopropyl, hydrazone R4 is -C02H; and R5, R6 and R7 are fluorene. Preferred compounds of formula V 1 are among them: where R is aryl and R10 is selected From: halogen, _ (Ci_C | 〇) alkyl, _ (Ci_Ci〇) alkoxy, -S- (匸 丨-<: 10) alkyl, and halogen ((:: 丨 _ (^ 〇) alkyl And 1 is an integer from 0 to 5; R2 is selected from: halogen, cyclopropyl, methyl, ethyl, 0-methyl, or S-methyl; and R5 is fluorene. Even more preferred is the compound of formula V1 : -20- This paper size applies to Chinese National Standard (CNS) A4 (210 X 297 mm) Order · -line · 472041 A7 B7 (CH,)

五、發明說明(18) R爲苯基或甲苯基; R1爲 R10選自:鹵素、-(CrC4)烷基、-(C「C4)烷氧基、-SCCVCJ 基及鹵素((^-(^燒基,且t爲2 ; R2爲甲基、乙基或丙基;且 R5爲 Η。 式V1化合物之較佳取代基包括下列:V. Description of the invention (18) R is phenyl or tolyl; R1 is R10 selected from: halogen,-(CrC4) alkyl,-(C "C4) alkoxy, -SCCVCJ group and halogen ((^-( R2 is methyl, t is 2; R2 is methyl, ethyl, or propyl; and R5 is fluorene. Preferred substituents for compounds of formula V1 include the following:

CH (ch2)〇2- (a) R1 爲 ----.---------^裳--- (請先閱讀背面之注意事寫本頁) 訂: -CH; ,ίο 經濟部智慧財產局員工消費合作社印製 ' (b) R1 爲 (c) R1 爲- (CrCu)院基; (d) R1Q選自:-(CrC6)烷基及-(CVCJ烷氧基; (e) R10選自:-S(CrC6)烷基及鹵素(CVQ)览基; (f) t爲0至3 (包括0與3 )之整數;(g) R2選自:氫、鹵素、-(eve〕)烷基及-occvc^)烷基 (h) R2選自:-0(CrC2)烷基及-SCCVCJ^基; (i) R2選自:芳基及芳氧基; · -21 .線_ 本紙張尺度適用中國國家標準(CNS〉A4規格(210 X 297公釐) ,472041 A7 B7_ 五、發明說明(19) (j) R2爲 HET ; (k) R5選自:氫、(CVC6)烷基及((^-(:6)烷氧基; ⑴ R5選自··鹵素(CVC6)烷氧基及鹵素(c2-C6)烷基; (m) R5選自:溴、氯、氟及碘; (n) R5爲芳基。_ 可依本發明方法製備之化合物包括: ((3-(2 -胺基-1,2-二氧乙基)-2-甲基-1-(苯甲基)_1Η-喇哚-4-基) 氧)乙酸; (Π-2-((3-(2-胺基-1,2-二氧乙基)-2-甲基-1-(苯甲基)_ιη-吲哚 -4-基)氧)丙酸; ((3-(2 -月:*•基-1,2 - 一氣乙基)-1-((1,1, -聯苯基)-2 -基甲基)-2 -甲 基-1Η-Θ丨哚-4-基)氧)乙酸; ((3-(2 -胺基-1,2 - 一乳乙基)-1-((1,1’ -聯苯基)-3-基甲基)-2 -甲 基-1H-叫丨哚-4-基)氧)乙酸; ((3-(2 -胺基-1,2-二氧乙基)-1-((1,1’_聯苯基)_4-基甲基)-2 -甲 基-1H-钊哚-4-基)氧)乙酸; ((3-(2 -胺基-1,2-二氧乙基)-1-((2,6-二氯苯基)甲基)-2 -甲基- 1H-吲哚-4-基)氧)乙酸; ((3-(2 -胺基-1,2-·—氧乙基)-1-((4 -氣苯基)甲基)-2 -甲基—1H-吲哚-4-基)氧)乙酸; ((3-(2-胺基-1,2-二氧乙基)-2-甲基-1-((萘基)甲基)_1H_啕哚_ 4-基)氧)乙酸; ((3-(2 -胺基-1,2-二氧乙基)-2 -乙基-1-(苯甲基朵-4-基) 氧)乙酸; -22- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------·-------果--- (請先閱讀背面之注意事項寫本頁) _ 經濟部智慧財產局員工消費合作社印製 472041 A7 B7 五、發明說明(20) ((3-(2-胺基-1,2-二氧乙基)-1-((3-氣苯甲基)-2 -乙基-1H-吲哚 -4-基)氧)乙酸; ((3-(2-版基-1,2 - 一乳乙基)-1-((1,1’ -聯苯基)-2-基甲基)-2 -乙 基-1H-吲哚-4-基)氧)乙酸; ((3-(2-胺基-1,2-二氧乙基聯苯基基甲基)_2_丙 基-1Η-4哚-4-基)氧)乙酸; ((3-(2 -胺基-1,2-二氧乙基)-2-環丙基-1-(苯甲基卜朵- 4-基)氧)乙酸; ((3-(2 -胺基-1,2 -一乳乙基)-1-((1,11-聯苯基)_2_基甲基)-2 -環 丙基-lfi-啕哚-4-基)氧)乙酸; 4-((3-(2-胺基-1,2-二氧乙基)-2-乙基-1-(苯甲基)-lH-啕哚-4- 基)氧)丁酸; ((3-(2 -胺基-1,2 -二氧乙基)-2 -乙基-1-(苯甲基)-1Η-ρ弓丨嗓-4-基) 氧乙酸; ((3-(2 -胺基-1,2-二氧乙基)-2 -乙基-6-曱基-1-(苯甲基)-lH-11引 哚-4-基)氧)乙酸; ((3-(2-胺基-1,2-二氧乙基)-2,6-二甲基-1-(苯甲基哚-4-基)氧)乙酸; ((3-(2-胺基-1,2-二氧乙基)-2-甲基-1-(苯甲基)-lH-啕哚-4-基) 氧)乙酸; ((3-(2 -胺基-1,2-二氧乙基)-6 -乙基-2-甲基-1-(苯甲基)_1H-吲 哚-4-基)氧)乙酸; ((3-(2 -胺基-1,2-二氧乙基)-2,6-二乙基-1-(苯曱基弓卜朵-4-基)氧)乙酸; -23- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --I.---.-------裝--- 請先閱讀背面之注意事寫本頁) 訂· 線· 經濟部智慧財產局員工消費合作社印製 472041 經濟部智慧財產局員工消費合作社印製 五、發明說明(21) Α7 Β7CH (ch2) 〇2- (a) R1 is ----.--------- ^ Shang --- (Please read the notes on the back first and write this page) Order: -CH ;, ίο Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs' (b) R1 is (c) R1 is-(CrCu) courtyard; (d) R1Q is selected from:-(CrC6) alkyl and-(CVCJ alkoxy; e) R10 is selected from: -S (CrC6) alkyl and halogen (CVQ) alkyl; (f) t is an integer from 0 to 3 (including 0 and 3); (g) R2 is selected from: hydrogen, halogen,- (eve)) alkyl and -occvc ^) alkyl (h) R2 is selected from: -0 (CrC2) alkyl and -SCCVCJ ^; (i) R2 is selected from: aryl and aryloxy;--21 .Line _ This paper size applies to Chinese national standards (CNS> A4 (210 X 297 mm), 472041 A7 B7_ V. Description of the invention (19) (j) R2 is HET; (k) R5 is selected from: hydrogen, ( CVC6) alkyl and ((^-(: 6) alkoxy); ⑴ R5 is selected from ·· halogen (CVC6) alkoxy and halogen (c2-C6) alkyl; (m) R5 is selected from: bromine, chlorine , Fluorine and iodine; (n) R5 is aryl. The compounds that can be prepared according to the method of the present invention include: ((3- (2-amino-1,2-dioxyethyl) -2-methyl-1 -(Benzyl) _1Η-raldol-4-yl) oxy) acetic acid; (Π-2-((3- (2-amino- 1,2-dioxoethyl) -2-methyl-1- (benzyl) _ιη-indole-4-yl) oxy) propionic acid; ((3- (2 -month: * • yl-1 , 2 -monoethyl) -1-((1,1, -biphenyl) -2-ylmethyl) -2-methyl-1Η-Θ 丨 indol-4-yl) oxy) acetic acid; (( 3- (2-amino-1,2-monolactyl) -1-((1,1'-biphenyl) -3-ylmethyl) -2-methyl-1H- is called indole- 4-yl) oxy) acetic acid; ((3- (2-amino-1,2-dioxyethyl) -1-((1,1'_biphenyl) _4-ylmethyl) -2- Methyl-1H-zolin-4-yl) oxy) acetic acid; ((3- (2-aminoamino-1,2-dioxoethyl) -1-((2,6-dichlorophenyl) methyl Yl) -2-methyl-1H-indole-4-yl) oxy) acetic acid; ((3- (2-amino-1,2- · -oxyethyl) -1-((4-gasbenzene (Methyl) -2) methyl-1H-indol-4-yl) oxy) acetic acid; ((3- (2-amino-1,2-dioxyethyl) -2-methyl-1 -((Naphthyl) methyl) _1H_oxindole_4-yl) oxy) acetic acid; ((3- (2-amino-1,2-dioxoethyl) -2-ethyl-1- ( Benzhydryl-4-yl) oxygen) acetic acid; -22- This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) ------ · ------- Fruit --- (Please read first Note on this page) _ Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 472041 A7 B7 V. Description of the invention (20) ((3- (2-amino-1,2-dioxyethyl) -1 -((3-Gaphenylmethyl) -2 -ethyl-1H-indole-4-yl) oxy) acetic acid; ((3- (2-benzyl-1,2 -monolactyl) -1 -((1,1'-biphenyl) -2-ylmethyl) -2-ethyl-1H-indol-4-yl) oxy) acetic acid; ((3- (2-amino-1, 2-dioxoethylbiphenylylmethyl) _2-propyl-1Η-4indole-4-yl) oxy) acetic acid; ((3- (2-amino-1,2-dioxyethyl) -2-cyclopropyl-1- (benzylbutorol-4-yl) oxy) acetic acid; ((3- (2-amino-1,2-monolactyl) -1-((1, 11-biphenyl) -2-ylmethyl) -2 -cyclopropyl-lfi-pyridin-4-yl) oxy) acetic acid; 4-((3- (2-amino-1,2-dioxo Ethyl) -2-ethyl-1- (benzyl) -lH-pyridin-4-yl) oxy) butanoic acid; ((3- (2-amino-1,2-dioxoethyl) -2 -Ethyl-1- (benzyl) -1Η-ρ 弓 -4-yl) oxyacetic acid; ((3- (2-amino-1,2-dioxyethyl) -2- Ethyl-6-fluorenyl-1- (benzyl) -lH-11indol-4-yl) oxy) acetic acid; ((3- (2-amino-1,2-dioxoethyl -2,6-dimethyl-1- (benzylindol-4-yl) oxy) acetic acid; ((3- (2-amino-1,2-dioxoethyl) -2-methyl- 1- (benzyl) -lH-pyridin-4-yl) oxy) acetic acid; ((3- (2-amino-1,2-dioxoethyl) -6-ethyl-2-methyl 1- (benzyl) _1H-indole-4-yl) oxy) acetic acid; ((3- (2-amino-1,2-dioxoethyl) -2,6-diethyl-1 -(Benzylpyridyl-4-butoxy) oxy) acetic acid; -23- This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) --I .---.--- ---- Equipment --- Please read the note on the back to write this page) Order · Line · Printed by the Consumers 'Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 472041 Printed by the Employees' Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs ) Α7 Β7

((3-(2-胺基十2_二氧乙基)_2_甲基_6_苯氧基小(笨甲 吲哚-4-基)氧)乙酸; 土)'1^ ((3-(胺氧乙醯基)_2_乙基_6_甲基小(苯曱基)_ih饲哚 氧)乙酸;與 ''土 ) ((3-(2-胺基_1)2_二氧乙基)_2•乙基_6_苯氧基_!·(苯甲基卜出, ㈤噪-4-基)氧)乙酸或其醫藥上可接受之鹽。 此等化合物中,較佳化合物包括: (0-(2-胺基-丨,2_二氧乙基)_2_乙基(苯甲基卜…丨哚-斗 氧乙酸; ((3-(2-胺墓_1,2_二氧乙基)_2_乙基_6_曱基_1_ (苯甲基)-1Η-叫丨 ___-___Γ_____ 1 * I I 請先閱讀背面之注意事寫本頁) 嗓-4-基)氧)乙酸; ((3-(2-胺基_丨,2_二氧乙基)_2,6_二甲基]_(苯甲基丨哚_ 4-基)氧)乙酸; (0-(2-胺基_ι,2-二氧乙基)_2_甲基-1-(苯曱基)_1Η_ 氧)乙酸; ((3-(2-胺基-1,2_二氧乙基)_6-乙基_2-甲基_ 嗓-4-基)氧)乙酸; ((3-(2-胺基_1)2_二氧乙基)_2,6_二乙基_丨_(苯甲基出吲哚_ 4_基)氧)乙酸; ((3-(2-胺基-L2-二氧乙基)_2_甲基_6_苯氧基_丨_(苯甲基)— β哚-4,基)氧)乙酸; ((3-(胺氧乙醯基)_2-乙基_6_甲基_丨_(苯甲基)_1Η_Ρ?丨哚基) 氧)乙酸;與 ((3-(2-胺基-U-二氧乙基)_2_乙基_6_苯氧基_i_(苯甲基) 吲哚-4-基) 笨甲基 訂 --線. 24- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公t ) 472041 A7 B7 五、發明說明(22) 吲哚-4-基)氧)乙酸或其醫藥上可接受之鹽。 此等化合物中,更佳化合物爲: ((3-(2-胺基-1,2-二氧乙基)-2-甲基-1-(苯曱基)-1Η-θ丨哚-4-基) 氧)乙酸與((3-(2 -胺基-1,2-二氧乙基)-2-乙基-1-(苯甲基)_ 1H-啕哚-4-基)氧乙酸。 可依本方法製備之最佳化合物爲:((3 - (2 -胺基-1,2 -二氧 乙基)-2-乙基-1-(苯甲基丨嗓-4-基)氧乙酸或其醫藥上 可接受之鹽。 本發明方法提供一種使用價廉,容易取得之試劑合成式I 化合物之?i良法,如下列圖I所示:((3- (2-Aminododecyl 2-dioxyethyl) _2_methyl_6_phenoxy small (benzylindol-4-yl) oxy) acetic acid; earth) '1 ^ ((3 -(Amineoxyethylamido) _2_ethyl_6_methyl small (phenylamidinyl) _ih indolyloxy) acetic acid; and `` Earth '' ((3- (2-amino_1) 2_Di (Oxyethyl) _2 • ethyl_6_phenoxy_! · (Benzyl group, sulfol-4-yl) oxy) acetic acid or a pharmaceutically acceptable salt thereof. Among these compounds, preferred compounds include: (0- (2-amino-, 2, _dioxoethyl) _2_ethyl (benzylbu ... ... indole-dooxyacetic acid; ((3- ( 2-amine grave_1, 2_dioxyethyl) _2_ethyl_6_fluorenyl_1_ (benzyl) -1Η-called 丨 ___-___ Γ _____ 1 * II Please read the notes on the back first On this page) 4- (4-yl) oxy) acetic acid; ((3- (2-amino_ 丨, 2_dioxyethyl) _2,6_dimethyl] _ (benzyl 丨 indol_ 4- (Oxy) oxy) acetic acid; (0- (2-amino_ι, 2-dioxoethyl) _2_methyl-1- (phenylfluorenyl) _1Η_oxy) acetic acid; ((3- (2-amino -1,2_dioxyethyl) _6-ethyl_2-methyl_methyl-4-yl) oxy) acetic acid; ((3- (2-amino_1) 2_dioxyethyl) _2 , 6_diethyl_ 丨 _ (benzylindol_4-yl) oxy) acetic acid; ((3- (2-amino-L2-dioxoethyl) _2_methyl_6_benzene Oxy_ 丨 _ (benzyl) — βindole-4, yl) oxy) acetic acid; ((3- (aminooxyethylamidine) _2-ethyl_6_methyl_ 丨 _ (phenylmethyl) _1Η_Ρ? 丨 indolyl) oxy) acetic acid; and ((3- (2-amino-U-dioxyethyl) _2_ethyl_6_phenoxy_i_ (benzyl) indol-4- Base) Stupid methyl staple-thread. 24- This paper size is applicable National Standard (CNS) A4 (210 X 297 g) 472041 A7 B7 V. Description of the invention (22) Indole-4-yl) oxy) acetic acid or a pharmaceutically acceptable salt thereof. Among these compounds, more The preferred compounds are: ((3- (2-amino-1,2-dioxoethyl) -2-methyl-1- (phenylfluorenyl) -1Η-θ 丨 indol-4-yl) oxy) acetic acid With ((3- (2-amino-1,2-dioxoethyl) -2-ethyl-1- (benzyl) -1H-pyridin-4-yl) oxyacetic acid. According to this method The best compound to be prepared is: ((3-(2-amino-1,2-dioxyethyl) -2-ethyl-1- (benzyl-4-hexyl) oxyacetic acid or its medicine The method of the present invention provides a good method for synthesizing a compound of formula I using a reagent that is inexpensive and easy to obtain, as shown in the following Figure I:

圖I (請先閱讀背面之注意事 π寫本頁) 裝 經濟部智慧1產局員工消費合作社印製Figure I (Please read the note on the back first, write this page)

-25--25-

. 線· 本紙張尺度適用中國國家標準(CNS)A4規格(210 >= 297公釐) 472039 A7 五、發明說明(23)Line · This paper size is in accordance with Chinese National Standard (CNS) A4 (210 > = 297 mm) 472039 A7 V. Description of Invention (23)

RR

經濟部智慧財產局員工消費合作社印製 由i同(V)溶於合適滚碑,丨φ , ,'A 中.,以非質子性溶劑(如:甲苯彳較 佳。其他合適溶劑包括(作 T冬)車又 U—不限於):四氫呋喃(THF)、二 ^甲___、二氧陸園 '或丙酉同。受質/溶劑溶液若 要時H波處理或稍微加熱,以加速溶解。 溶劑之用’量應足以確保所古 隹侏所有化合物均保持溶液態直到完成 所需反應爲止。 ^ 溶液經鹼處理,以烷醇鹽鹼較 ξ 碰理:”Rw基、芳 爲(C丨-C6):t元氧基、齒素或 u (JL〇2(CrC6)烷基。亞磺酸化試劑 可根據J.W.威特(W叫等人,J· 0rg Chem,1967, 32,勒之 方法製備。較佳亞磺酸化試劑包括對甲苯基亞磺酸甲酯 苯亞績酸甲g旨或對甲苯録亞魏異了料。較佳梗醇 鹼包栝:.納、鉀或鋰之〒醇鹽或乙醇鹽鹼。以甲醇鉀特 佳。其他合適鹼包括(但不限於):氫化鈉、或LDA。通常 之用量爲起始物之約0.75至1 〇當量;以約1至約3當量 佳;約2當量最佳。 反應可在約15C至回流溫度下進行,且實質上在1至24 時内冗成。單離中間物V1時,係於1 5 〇C至5 〇 °C之溫度下 行反應’以25°C至40°C較佳’ 30°C更佳。若反應在6〇。匚至 -26- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 甲 必 鹽 別 驗 較 (請先閱讀背面之注意事^ -—裝--- ^填寫本頁) -線· 472041 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(24) 流溫度下進仃時,中間物V轉化成V〗之反應會迅速進行, 以75°C至85°C較佳,以8〇〇c更佳。 亞磺酸化試劑之用量並不重要,然而其用量爲吡咯起始物 (V)( —莫耳當量或過量時,最適合完成反應。 VA另一種製法中,以式R2〇SSR2◦二硫化物(其中R2〇爲烷 基或芳基)置換亞磺酸化試劑。硫化物中間物之氧化法係使 用適當氧化劑(如:過氧化氫或間氣過苯甲酸)完成。' 4哚(IVM艮容易再使用XCH2R4a烷化劑,其中乂爲合適脱 離基,尺“爲受保護之叛基、續醯基或鱗酸根,以受酷基保 護較佳’於驗之存在下院化。溴乙酸甲醋爲較佳燒化劑。 合適鹼包括:碳酸鉀、碳酸鈉、碳酸鋰、碳酸铯、碳2 鈉、碳酸氫鉀或氫氧化鉀。以碳酸鉀較佳。烷化劑 並不重要,然而烷化劑之用量超過起始物一莫冬旦 最適合完成反應。該反應於有機溶劑中進行較佳,= 酮、乙腈或二甲基甲醯胺。其他合適溶劑包掊㈠:不 於):甲醇、甲苯、四氫吱喃、甲基乙基酮、乙腈、或第 丁基甲基醚。該反應於約(TM⑼。C之溫度下反應,以 較佳’且實質上約:1至24小時内即可完成反應,端賴所採; 反應物及如:反應溫度之條件而定。 需要時,可使用移相試劑如:四丁基銨化鎮。 乙一酿胺II之製法很容易依兩步職方法完成 0·2至1.5毫莫耳之草㈣(以與起始物等莫耳濃度較佳 中間物出。溶剖爲二氣甲烷、氣仿、三氣乙 晞、或甲苯較佳。合適溫度至周溫,^ 較佳。 氫 量 丙 限 溫 約 理 化 ----.---·-------裝--- <:請先閲讀背面之注意事寫本頁) --線 -27 本紙張尺度適用中國國玄標準(CNS)A4規格(21〇 x 、 472041 A7 五、發明說明(25) 使二以氨處理此溶液;可呈氣體通人,或最好 。/ D旲 足30%氨水溶液。該反應主要在約_25π至 二進行,以約-2。滅較佳’實質上在1〇分鐘 内即可完成。 j才 解反應係使用驗完成,如:氫氧化卸、氫氧化麵或 ^ ..内,以氫氧化鈉較佳,其係於低碳數醇溶劑中(如: 乙醇、異丙醇,等等)或於如:四氫咳喃、二氧陸園 及丙酮疋溶劑中進行。 可採用標準分析技術(如:HPLC)追踪圖I之反應,以測定 起始物與中間物何時轉化成產物。 。可=離中間物…與IV。例如:分離中間物j v時,可使用 三、晷液及與水互A之溶劑萃取含於合適有機溶劑(如:甲 苯)中(IV溶液。水層之最初pH必須大於12。分層,調整 水層Ρ—Η至1至12之範圍内,以9至11.5較佳,11最佳。最好 利用萃取法,使用可溶解中間物之有機溶劑萃取水層中之 中間物IV。水層之最初ΡΗ必須大於1 2。鹼之濃度約0.5 Ν 至5Nk佳,約丨.5 1^至2 5 Ν更佳。鹼之最佳濃度爲2Ν。與 ^互给'之合適落劑包括(但不限於):甲醇、丙酮、異丙 酉予乙知、二氧陸圜、或四氫呋喃。以甲醇較佳。雖然添 /、序並不重要,但當有機溶劑加至待萃取之中間物IV中 後,含中間物之水溶液之PH最好經過調整。 下圖1(a)説明上述製備中間物IV(雙爐法。可採用標準層 析去單離及純化中間物V 1。 -28- 本紙張尺度適財國國家標準(CNS)A4規格(21〇 X 297公楚 ----------------裝--- (請先閉讀背面之注意事寫本頁) 訂· .線. 經濟部智慧財產局員工消費合作社印製 472041 A7Printed by the Consumers 'Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs, which is dissolved in suitable rolling monuments, 丨 φ,,' A. (i) with aprotic solvents (such as toluene 彳 is preferred. Other suitable solvents include (for (T winter) cars and U—not limited to): Tetrahydrofuran (THF), Dimethyl ____, Dioxin Land 'or Propylamine. The substrate / solvent solution is H-wave treated or heated slightly if necessary to accelerate dissolution. The amount of the solvent used should be sufficient to ensure that all the compounds in the ancient palates remain in solution until the desired reaction is completed. ^ The solution is treated with alkali, and the alkoxide base is more reasonable than ξ: "Rw group, aryl is (C 丨 -C6): t-membered oxygen, dentin, or u (JL〇2 (CrC6) alkyl. Sulfin Acidifying reagents can be prepared according to the method of JW Witte (W. et al., J. 0rg Chem, 1967, 32, Le.). Preferred sulfinating reagents include methyl p-tolyl sulfinate and benzoic acid g. Paratoluene is a different ingredient. Preferable alcohol bases include: sodium, potassium, or lithium alkoxide or ethanolate base. Particularly preferred is potassium methoxide. Other suitable bases include (but are not limited to): sodium hydride Or LDA. The usual amount is about 0.75 to 10 equivalents of the starting material; preferably about 1 to about 3 equivalents; about 2 equivalents is best. The reaction can be carried out at about 15C to reflux temperature, and substantially at 1 It is redundant until 24 o'clock. When the intermediate V1 is isolated, the reaction is performed at a temperature of 150 ° C to 50 ° C, and the reaction temperature is preferably 25 ° C to 40 ° C, and 30 ° C is better. 60. 匚 to -26- This paper size is applicable to Chinese National Standard (CNS) A4 (210 x 297 mm). A salt must be checked. (Please read the precautions on the back first. ^ -—— 装 --- ^ fill in (This page)-Line · 47 2041 A7 B7 Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. 5. Description of the invention (24) The reaction of the intermediate V to V will proceed quickly when it is fed at a stream temperature, preferably 75 ° C to 85 ° C. It is more preferably 800c. The amount of sulfinating reagent is not important, but the amount is the pyrrole starting material (V) (-Molar equivalent or excess, it is most suitable to complete the reaction. In another method of VA, Replace the sulfinating reagent with the formula R2〇SSR2 ◦ disulfide (where R2 is alkyl or aryl). The sulfide intermediate is oxidized by using an appropriate oxidant (such as hydrogen peroxide or methane perbenzoic acid) Completed. '4 indole (IVM) is easy to use XCH2R4a alkylating agent, in which 乂 is a suitable leaving group, the rule "is a protected renyl group, fluorenyl group or phosphonate, it is better to be protected by kuyi" It is chemically treated in the presence of methyl bromide. Methyl bromoacetate is the preferred calcining agent. Suitable bases include: potassium carbonate, sodium carbonate, lithium carbonate, cesium carbonate, sodium carbonate, potassium bicarbonate, or potassium hydroxide. Potassium carbonate is preferred. The alkylating agent is not important, but the amount of the alkylating agent exceeds the starting material-mordane Most suitable to complete the reaction. This reaction is best performed in an organic solvent, = ketone, acetonitrile or dimethylformamide. Other suitable solvents include: not more than): methanol, toluene, tetrahydrofuran, methyl ethyl Ketone, acetonitrile, or butyl methyl ether. The reaction is carried out at a temperature of about (TM⑼.C), preferably 'and substantially about: the reaction can be completed within 1 to 24 hours, depending on the choice; reactants And such as: the conditions of the reaction temperature. When needed, phase-shifting reagents such as: tetrabutylammonium can be used. The method for the production of ethyl amine II can be easily completed in a two-step method from 0.2 to 1.5 millimoles. Grasshopper (in the middle of the mole concentration with the starting material is preferred. The dissolution profile is preferably digas methane, gas imitation, trigas acetamidine, or toluene. Suitable temperature to ambient temperature, ^ is preferred. Physical and Chemical Limitation of Hydrogen Content Limit Temperature ----.------------ Loading --- <: Please read the note on the back first and write this page) ---- 27 This paper size applies China National Xuan Standard (CNS) A4 specifications (21 ×, 472041 A7 V. Description of the invention (25) Use two to treat this solution with ammonia; it can be a gas, or the best. / D 30% ammonia solution. The reaction is mainly carried out at about _25π to 2 and is about -2. It is better to complete the reaction in substantially 10 minutes. The reaction can be completed using tests such as: unloading of hydroxide, hydroxide or ^ .. Among them, sodium hydroxide is preferred, which is in a low carbon number alcohol solvent (such as ethanol, isopropanol, etc.) or in a solvent such as tetrahydrogran, dioxin and acetone. Standard analysis techniques (such as: HPLC) can be used to track the reaction in Figure I to determine when the starting materials and intermediates are converted to products.... Can be separated from the intermediates ... and IV. For example, when separating the intermediate jv, It can be extracted with a suitable solvent (such as toluene) by using three or three solvents and a solvent with water (IV solution. The initial pH of the aqueous layer must be greater than 12. Layering, The whole water layer is in the range of P—Η to 1 to 12, preferably 9 to 11.5, and 11 is the best. It is best to use the extraction method to extract the intermediate IV in the water layer using an organic solvent that can dissolve the intermediate. The water layer The initial pH must be greater than 12. The concentration of the base is preferably about 0.5 N to 5Nk, and more preferably about .5 1 ^ to 2 5 N. The optimal concentration of the base is 2N. Suitable agents for mutual feeding include: ( (But not limited to): methanol, acetone, isopropyl hydrazone to Ethyl, dioxolane, or tetrahydrofuran. Methanol is preferred. Although the order is not important, when the organic solvent is added to the intermediate IV to be extracted IV After the intermediate, the pH of the aqueous solution containing the intermediate is preferably adjusted. The following figure 1 (a) illustrates the above preparation of the intermediate IV (dual furnace method. Standard chromatography can be used to separate and purify the intermediate V 1. -28- Paper Standards: National Standards (CNS) A4 Specification (21〇X 297) ----------------------- (Please close the cautionary note on the back (Page) Order · .Line. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 472041 A7

相關技藝專家們很容易了解;上述方法之起妒 取得或很容易利用已知技術,由市售起始物製物可自商品 起始物ν'係根據下列方法製.備,。. · °Relevant art experts are easy to understand; the above methods are jealous to obtain or easily use known techniques. Products made from commercially available starting materials can be prepared from commercial products. Starting material ν 'is prepared according to the following methods. · °

Mil ------------------ (請先閱讀背面之注意事寫本I) 經濟部智慧財產局員工消費合作社印製Mil ------------------ (Please read the notes on the back of the book I) Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs

.. .線_ 472041 A7 B7 五、發明說明(27) R8爲(c「c6)烷基或芳基。 由通當取代之丙醯乙酸酯乂先經硫醯氣鹵化,其用量最好 與起始物呈等莫耳濃度,於約0°C至25Ό之溫度下進行,以 15°C以下較佳,製備IX。 IX &lt;水解及脱除羧基反應係使用水性酸(如:鹽酸)回流 約1至24小時後完成。中和含脱除羧基產物νιπ之溶液,調 至pH約7.0-7.5,然後與環己二酮νπ(等莫耳濃度較佳)及鹼 (如氫氧化鈉較佳)反應,產生三酮單水合物VI沈澱物,若 需要時可以純化及單離。該反應最好在_2〇。〇至周溫之溫度 下進行,_£貫質上在約i至2 4小時内可完成反應。 上述反應最好依”單爐法&quot;進行,依上述指定之順序添加 反應物至反應容器中。較佳者,在未單離式以或νιπ化合 物下即可進行反應,以避免曝露到此等揮發性催淚毒氣。 V之製法係由VI於可與水共沸之高沸點非極性溶劑(以甲 苯較佳)中,與等莫耳之式R1NH2回流,其中R1&amp;上述定 義。 以沸點至少1 00°C之溶劑較佳,如:甲苯、二甲苯、缴花 烴、苯、1,2-二氣乙烷或1,3,5-三甲基苯,因此不需要使用 加壓反應器。應使用足量溶劑,確保所有化合物保持溶液 態至反應實質上在約1至2 4小時内完成爲止。 Ο 較佳製程〇中,於酸催化之反應中製備亞磺酸化試劑, 其係由式RS-ΟΜ適當芳基亞讀酸鹽,其中M爲鹼金屬(以鈉 权佳),且R爲-(CrC6)烷基、芳基或經取代芳基(以苯基或 -30- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ---L---*-------裝--- 請先閱讀背面之注意事寫本頁) 訂.. ,線_ 經濟部智慧財產局員工消費合作社印製 472041 A7 ____B7 五、發明說明(28) 曱苯基較佳),與酸(以鹽酸較佳)反應。該反應最好在周严 下,以15至3CTC較佳,20至25。(:更佳,於相應於所需酯2 物之醇溶劑中(以甲醇較佳) ΟII RSX, 進行。其他合適溶劑包括乙醇與異丙醇。另一種製程中, 使用一當量所需醇,於合適之非質子性溶劑(如:甲中 操作。更佳者,該反應使用過量醇,於溶劑中操作,最好 在無溶劑之相應於所需酯產物之醇中操作 0II RSX, 該反應最好使用相對於亞磺酸鹽起始物過旦 &lt;! ~莫耳之酸 行0 下列實例進一步説明本發明方法,該等每u、 A , 亨馬例亦説明本發明 中間化合物之製法。該等實例僅供説明用 J用且並未以任何 式限制本發明範圍。 製法1 (土)對甲苯亞磺酸甲酉旨 進 方 ---Γ-------------- (請先閱讀背面之注意事寫本頁) 訂· --線. 經濟部智慧財產局員工消費合作社印製.. _ Line 472041 A7 B7 V. Description of the invention (27) R8 is (c "c6) alkyl or aryl group. Propyl acetate substituted by Tongdang is first halogenated with sulfur gas, and its dosage is the best. It is equimolar with the starting material and is carried out at a temperature of about 0 ° C to 25 ° C, preferably below 15 ° C, to prepare IX. IX &lt; The hydrolysis and removal of carboxyl reaction system uses an aqueous acid (such as: hydrochloric acid ) Complete reflux after about 1 to 24 hours. Neutralize the solution containing carboxyl removal product νιπ, adjust the pH to about 7.0-7.5, and then combine with cyclohexanedione νπ (equivalent molar concentration is preferred) and alkali (such as hydroxide Sodium is preferred) to produce a triketone monohydrate VI precipitate, which can be purified and isolated if necessary. The reaction is preferably carried out at a temperature of from 20.0 to ambient temperature, and qualitatively at about 1 to The reaction can be completed within 4 hours. The above reaction is best performed according to the "single furnace method", and the reactants are added to the reaction container in the order specified above. Preferably, the reaction can be carried out in a non-single-isolated compound or νιπ compound to avoid exposure to such volatile tear gas. The method for preparing V is based on the reflux of VI in a high boiling point non-polar solvent (preferably toluene) which can be azeotropic with water, and R1NH2 of equal formula, wherein R1 &amp; Solvents with a boiling point of at least 100 ° C are preferred, such as: toluene, xylene, croton, benzene, 1,2-digasethane, or 1,3,5-trimethylbenzene. Pressure reactor. A sufficient amount of solvent should be used to ensure that all compounds remain in solution until the reaction is substantially complete in about 1 to 24 hours. 〇 In a preferred process 〇, a sulfination reagent is prepared in an acid-catalyzed reaction, which is an appropriate aryl sulfinate of the formula RS-OM, where M is an alkali metal (with sodium right), and R is- (CrC6) Alkyl, aryl or substituted aryl (Phenyl or -30- This paper size applies to China National Standard (CNS) A4 specification (210 X 297 mm) --- L --- *- ----- Install --- Please read the note on the back to write this page) Order .., line _ Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 472041 A7 ____B7 V. Description of the invention (28) It is preferred to react with acid (preferably hydrochloric acid). The reaction is preferably carried out under severe conditions, preferably 15 to 3 CTC, and 20 to 25. (: Better, in an alcohol solvent (preferably methanol) corresponding to the desired ester 2) RSII. Other suitable solvents include ethanol and isopropanol. In another process, one equivalent of the required alcohol is used. The reaction is performed in a suitable aprotic solvent (such as: A. More preferably, the reaction uses an excess of alcohol and is operated in a solvent, preferably in a solvent-free alcohol corresponding to the desired ester product. It is best to use <!! Moore's acid line relative to the sulfinate starting material. The following examples further illustrate the method of the present invention, and these examples also illustrate the method of preparing the intermediate compounds of the present invention. These examples are for illustrative purposes only and do not limit the scope of the present invention in any formula. Method 1 (Earth) p-toluenesulfinic acid formazan formula --- Γ ---------- ---- (Please read the note on the back first and write this page) Order ·-. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs

IIII

Na HC1Na HC1

MeOHMeOH

在5升之三頸圓底燒瓶中添加2845亳升甲辟γ Τ ^(5倍體積)且 -31 - 家標準(CNS)A4規格⑵0 X 297公釐) 472041 A7 B7____ 五、發明說明(29) 通入165.58克(1.4當量,4.47莫耳)無水HCI,添加HC1至 ill Li — I- III — —-- - I (請先閱讀背面之注意事寫本頁)In a 3-liter three-necked round bottom flask of 5 liters was added 2845 liters of formazan γ ^ (5 times the volume) and -31-Standard (CNS) A4 specification (0 X 297 mm) 472041 A7 B7____ V. Description of the invention (29 ) Pass in 165.58 grams (1.4 equivalents, 4.47 mols) of anhydrous HCI, add HC1 to ill Li — I- III — —--I (Please read the notes on the back first to write this page)

MeOH期間會放熱。利用冷卻法及調整添加速度,保持燒瓶 溫度範圍在2 0至25Ό之間。添加甲苯亞磺酸鋼(丨.〇當量, 569克,3_19莫耳),於室溫下攪拌1至4小時。加入285〇毫升 (5倍體積),然後添加2850毫升甲苯(5倍體積)。混合物揽 拌1至30分鐘,使之分層。分層後取水層,各使用1425毫升 (2.5倍體積)甲苯回萃取,共2次。合併所有甲苯層,以各 1425毫升(2.5倍體積)1 Μ碳酸氫鈉溶液洗滌2次。分層,曱 苯層眞2濃縮至约3倍體積。全部於旋轉蒸發器中濃縮至少 量油,最終重量收量爲476.78克酯,理論値重量之87.7%。 製法2 ((2 -乙基-1- +甲基)-1Η-ρ5卜朵-4-基)氧)乙酸甲醋It exotherms during MeOH. Use the cooling method and adjust the addition speed to keep the temperature of the flask between 20 and 25 ° F. Toluene sulfinate steel (1.0 equivalent, 569 g, 3-19 mol) was added and stirred at room temperature for 1 to 4 hours. Add 2850 ml (5 times the volume) and then 2850 ml of toluene (5 times the volume). The mixture is stirred for 1 to 30 minutes to separate the layers. After the layers were separated, the aqueous layer was taken, and each was re-extracted with 1425 ml (2.5 times the volume) of toluene for a total of 2 times. All toluene layers were combined and washed twice with 1,425 ml (2.5 times the volume) of a 1 M sodium bicarbonate solution. The layers were separated and the benzene layer 眞 2 was concentrated to about 3 times the volume. All were concentrated in a rotary evaporator to at least a quantity of oil. The final weight yield was 476.78 grams of ester, 87.7% of theoretical weight. Production method 2 ((2-ethyl-1- + methyl) -1Η-ρ5budol-4-yl) oxy) methyl acetate

經濟部智慧財產局員工消費合作社印製 回流 取2 -(2 -氧丁基)環己燒-1,3 -二酮(1 00克,〇_ 5莫耳)释浮於 甲苯(600毫升)中。混合物加熱至85°C,攪拌5分鐘。於約 30至45分鐘内滴加苄胺(56.3克,(M莫耳,1.05當量)。添 -32- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公® ) 472041 A7 B7 五、發明說明(3〇) 加後混合物轉呈琥珀色溶液。加熱溶液,共彿排除水,直 到反應溫度達110 °C爲止。使反應於11 〇。〇下攙拌1小時,此 時蒸餾排除溶劑直到殘留300毫升甲苯爲止。在此含2 _乙基 -1,5,6,7-四氫-1-(苯甲基)-4H-吲哚-4-酮之溶液中添加含對甲 苯亞磺酸甲酯(127.5克,0.75莫耳)之300毫升甲苯與甲醇神 (11 0.5克’ 1.5莫耳)溶液。反應混合物於氮氣下,反應溫度 在30°C至40°C之間,攪拌2小時。TLC顯示起始物已完全消 耗。反應隨後冷卻至1 〇 °C,加水終止反應(5〇〇毫升)。攪拌 3 0分鐘後’添加甲苯(500毫升),分層。取含2 -乙基-5-[(4_ 甲苯基)亞磺醯基]-1-苄基-5,6,7-三氫啕哚-4-酮之曱苯溶液 於80°C下加熱2至3小時,此時由TLC證實反應已完成。溶 液冷卻至室溫。添加250毫升MeOH及3 12毫升2 N NaOH ,混 合物攪拌3 0分鐘。分層,以125毫升MeOH及1 56毫升2 N NaOH萃取有機層。分層,合併水層。添加甲苯(250毫升)至 水層中,以1 N HCI調整水層pH至1 1。分層,以1500毫升丙 酮稀釋有機層。添加碳酸鉀粉末(丨5 i. 8克,1.丨莫耳)及溴乙 酸甲酯(93.6克,0.6莫耳),使混合物於60 °C下攪拌1 6小 時。固體經聚丙烯過濾,以丙酮(300毫升)洗滌。取一份濾 液(6 0克,或總量之5 % )蒸發,黃色固體自異丙醇(5 5毫升) 中再結晶,產生標題化合物之灰白色固體(6.5克,82%收 率)。 實例1 ((2-乙基-1-(苯曱基)-1Η-叫哚-4-基)氧)乙酸甲酯之製法 A. 2 -乙基-1,5,6,7-四氫-1-(苯曱基)-4H-W哚-心酮之製法 -33- 本纸張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----^---·-------裝—— (請先閱讀背面之注意事*51^^寫本頁) 訂. •線. 經濟部智慧財產局員工消費合作社印製 472041 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(31) 取2-(2-氧丁基)環己烷-1,3-二酮(1000克,4.995莫耳)懸浮 於甲苯(6000毫升,6倍體積)。混合物回升至85»c,攪掉$ 分鐘。以約30至45分鐘滴加苄胺(562 6克,5·25莫耳,工 當量)。添加混合物後’轉呈琥珀色溶液。溶液加熱,共滞 排除水直到反應溫度達到11(TC爲止。反應於11〇。(:下授掉2 小時,此時於常壓下蒸餾排除约4〇〇〇毫升溶劑。溶液移至 燒瓶中’再洛發成玻箱色黏稠油,直接用於下—個步,驟 油重=1372.24克 理論値重量=1253.7克 效力= 87% 莫耳收率=95.2% B. 2-乙基-(苯甲基)-1Η-吲哚_4_醇之製法 取氫化鈉(400克,9.96莫耳,2.5當量)懸浮於丁hf(50〇〇毫 升,5倍體積)中。在懸浮液中添加上述a項化合物(U49 克,3.98莫耳,1當量),於20至25°C下攪拌至停止冒泡爲 止。添加對甲苯亞磺酸甲酯(1121克,6.59莫耳,1.65當 量),混合物加熱至30°C。約2.5小時後,當氣體釋出時混合 物變深色,並觀察到放熱至47°C。TLC顯示已完全消耗起始 物。反應隨後冷卻至0至5 C ’缓缓添加去離子水(5 〇 〇 〇毫 升,5倍體積)中止反應。再以冰醋酸(6〇〇克,1〇莫耳,25 當量)中止反應。以甲苯(5000毫升,5倍體積)稀釋混合物, 以飽和碳酸氫鈉(2500毫升,2.5倍體積)洗滌。上層有機層 以另2 5 0 0毫升飽和竣氣納洗蘇。合併水層,以甲苯($ 〇 〇 〇 毫升’ 5倍體積)回萃取。合併有機層,加熱至溫和回流(約 (請先閱讀背面之注意事 寫本頁) 裝 .線. -34- 本紙張尺度適用&gt; 國國家標準(CNS)A4規格(210 X 297公釐) 472041 Α7 Β7 五、發明說明(32) 80°C)並攪拌2小時,此時以TLC證實反應已完成。此深色溶 液於常壓下濃縮至約4000毫升,以飽和碳酸氫鈉( 1500毫升 X 2)洗滌。有機層經硫酸鎂脱水,眞空濃縮成深色黏胡 油,直接用於下一個步,驟。 C _ ((2-乙基-1-苯曱基-1H-Μ丨哚-4-基)氧)乙酸甲酯之製法 取2 -乙基-5-[(4-甲苯基)亞磺醯基]-1-芊基-5,6,7-三氫⑼嗓 -4-酮樣本經管柱層析法使用5〇%乙酸乙酯之己烷溶液純 化。清楚地分離出Rf 0.32之亞颯非對映異構物,並單離出 亞减非對映異構物之混合物(Rf 0.32與0.26)。於這兩份樣本 上進行'Hi^CNMR實驗: TLC Rf 0.32(1/1 己烷/Et0Ac)。A NMR(CDC13, 300 MHz)汐 7.51(dd, J = 6.6, 1.6, 1 H), 7.31-7.26(m, 5 Η), 6.88(d, J=6.4, 2 H), 6.38(d, J=8.1, 1 H)s 6.38(t, J=l, 1 H), 5.03(s, 2 H), 3.48-3.42(m, 1 H), 3.05-2.97(m, 1 H), 2.68-2.54(m, 2 H), 2.43-Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs, and taking 2-(2-oxobutyl) cyclohexyl-1,3-dione (100 g, 0_5 mol), released in toluene (600 ml) in. The mixture was heated to 85 ° C and stirred for 5 minutes. Add benzylamine (56.3 g, (M Mol, 1.05 eq.) Dropwise in about 30 to 45 minutes. Tim-32- This paper size applies to Chinese National Standard (CNS) A4 (210 X 297 male®) 472041 A7 B7 V. Description of the invention (30) After the addition, the mixture turns into an amber solution. Heat the solution to remove water until the reaction temperature reaches 110 ° C. Stir the reaction at 11.0 ° C for 1 hour, and then distill The solvent was eliminated until 300 ml of toluene remained. To this solution containing 2-ethyl-1,5,6,7-tetrahydro-1- (benzyl) -4H-indole-4-one was added Methyl toluene sulfinate (127.5 g, 0.75 mol) in 300 ml of toluene and methanol (11 0.5 g '1.5 mol) solution. The reaction mixture is under nitrogen at a reaction temperature between 30 ° C and 40 ° C. And stirred for 2 hours. TLC showed that the starting material was completely consumed. The reaction was then cooled to 10 ° C and the reaction was stopped by adding water (500 ml). After stirring for 30 minutes, 'toluene (500 ml) was added and the layers were separated. Benzene solution containing 2-ethyl-5-[(4_tolyl) sulfenamidinyl] -1-benzyl-5,6,7-trihydroxandin-4-one heated at 80 ° C 2 Up to 3 small At this time, the reaction was confirmed to be complete by TLC. The solution was cooled to room temperature. 250 ml of MeOH and 3 12 ml of 2 N NaOH were added, and the mixture was stirred for 30 minutes. The layers were separated and the organic was extracted with 125 ml of MeOH and 1 56 ml of 2 N NaOH. Layer. Separate layers and combine aqueous layers. Add toluene (250 mL) to the aqueous layer and adjust the pH of the aqueous layer to 1 with 1 N HCI. Separate the layers and dilute the organic layer with 1500 mL of acetone. Add potassium carbonate powder (5 i. 8 g, 1. mol) and methyl bromoacetate (93.6 g, 0.6 mol). The mixture was stirred at 60 ° C for 16 hours. The solid was filtered through polypropylene and washed with acetone (300 ml). A portion of the filtrate (60 g, or 5% of the total) was evaporated and the yellow solid was recrystallized from isopropanol (55 ml) to give the title compound as an off-white solid (6.5 g, 82% yield). Example 1 Preparation of ((2-ethyl-1- (phenylamidino) -1Η-called indol-4-yl) oxy) acetic acid methyl ester A. 2-ethyl-1,5,6,7-tetrahydro -1- (phenylhydrazone) -4H-W indole-cardione production method-33- This paper size is applicable to China National Standard (CNS) A4 specification (210 X 297 mm) ---- ^ --- · ------- install-(Please read first * 51 ^^ Write this page) Order. • Line. Printed by the Consumers ’Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 472041 A7 B7 Printed by the Employees’ Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 5. Description of the Invention (31) Take 2- (2-Oxybutyl) cyclohexane-1,3-dione (1000 g, 4.995 mol) was suspended in toluene (6000 ml, 6 volumes). The mixture rises to 85 »c and stirs for $ minutes. Benzylamine (562 6 g, 5.25 mol, eq.) Was added dropwise over about 30 to 45 minutes. After the addition of the mixture ', it turned into an amber solution. The solution was heated, and the water was removed by stagnation until the reaction temperature reached 11 ° C. The reaction was allowed to proceed at 10 ° C. (: 2 hours, and then about 4,000 ml of solvent was distilled off under normal pressure at this time. The solution was transferred to a flask 'Zai Luofa into a glass box-colored viscous oil, directly used in the next step, the weight of sudden oil = 1372.24 grams of theoretical weight = 1253.7 grams of efficacy = 87% Mohr yield = 95.2% B. 2-ethyl- ( Method for the preparation of benzyl) -14-indole-4_ol Sodium hydride (400 g, 9.96 moles, 2.5 equivalents) was suspended in butyl hf (500 ml, 5 times the volume). Added to the suspension The above compound a (U49 g, 3.98 moles, 1 equivalent), stirred at 20 to 25 ° C until the bubbling ceases. Add methyl p-toluenesulfinate (1121 g, 6.59 moles, 1.65 equivalents), The mixture was heated to 30 ° C. After about 2.5 hours, the mixture became darker when the gas was released and an exotherm was observed to 47 ° C. TLC showed that the starting material had been completely consumed. The reaction was then cooled to 0 to 5 C 'slowly Slowly add deionized water (500 ml, 5 times volume) to stop the reaction. Then use glacial acetic acid (600 g, 10 moles, 25 equivalents) The reaction was stopped. The mixture was diluted with toluene (5000 ml, 5 times the volume) and washed with saturated sodium bicarbonate (2500 ml, 2.5 times the volume). The upper organic layer was saturated with another 2500 ml of saturated gas. Combined water Layer, extracted back with toluene ($ 000 ml '5 times volume). Combine the organic layers and heat to a gentle reflux (approximately (please read the note on the back first to write this page)). Line. -34- This paper size Applicable> National National Standard (CNS) A4 specification (210 X 297 mm) 472041 Α7 B7 V. Description of the invention (32) 80 ° C) and stirred for 2 hours, at this time, the reaction was confirmed by TLC. The dark solution Concentrated to about 4000 ml under normal pressure, washed with saturated sodium bicarbonate (1500 ml X 2). The organic layer was dehydrated with magnesium sulfate, emptied and concentrated to a dark viscous oil, and used directly in the next step, step. C _ Preparation of ((2-ethyl-1-phenylfluorenyl-1H-M 丨 in-4-yl) oxy) methyl acetate 2-ethyl-5-[(4-tolyl) sulfinamilide] A sample of -1-fluorenyl-5,6,7-trihydrofluoran-4-one was purified by column chromatography using 50% ethyl acetate in hexane. Rf 0.32 was clearly separated The diastereomers of the fluorene are separated and the mixture of the sub-minor diastereomers is isolated (Rf 0.32 and 0.26). The 'Hi ^ CNMR experiment was performed on these two samples: TLC Rf 0.32 (1 / 1 Hexane / Et0Ac). A NMR (CDC13, 300 MHz) Ti 7.51 (dd, J = 6.6, 1.6, 1 H), 7.31-7.26 (m, 5 Η), 6.88 (d, J = 6.4, 2 H ), 6.38 (d, J = 8.1, 1 H) s 6.38 (t, J = 1, 1 H), 5.03 (s, 2 H), 3.48-3.42 (m, 1 H), 3.05-2.97 (m, 1 H), 2.68-2.54 (m, 2 H), 2.43-

2.39(m, 5 H),2.23-2_18(m, 1 H),1.18(t,J=7.5,3 H)。13C NMR(CDC13, 75 MHz) ci 185.53, 143.86, 141.41, 139.45, 138.25, 136.15, 129.67, 129.02, 127.71, 125.47, 124.76, 120.10, 102.43, 71.62, 47.14, 21.77, 21.48,19.92,19.35,12.17。 TLC Rf 0.32 及 0.26(1/1 己烷/Et〇Ac)。iH NMR(CDC13, 500 MHz ’ Rf 0.26之共振無法分辨)82(山 J=7 2, 2 h), 6 33(s, 1 H), 4.94(dd, J=16.9, 23.9, 2 H), 4.01(dd, J=4.7, 9.1, 1 H) ° nc nmr(cdci3,觀察到所有共振)5 186 98, 186.33,144.82, 142.03, 140.06, 139.00, 137.58, 136.98, 136.85, 130.42, 130.1 1, 129.70, 129.65, 129.26, 128.37, 126.61, 126.27, 125.39, 120.91, -35- ϋ張尺度適用中國國家標準(CNS)^4規格(2丁〇_χ 297公餐) ----1---·-------装—— (請先閱讀背面之注意事寫本頁) -i-r-VJ· -線. 經濟部智慧財產局員工消費合作社印製 04 2 7 A7 __B7__. 五、發明說明(33) 120.74,103.04,102.77,71.97,69.72,61.Q1, 47 78, 47 72 22.11,21.90, 21.70, 21.30, 21.24, 20.68, 19.97’ 19.71 1489 12.84, 12.79。 D. ((2-乙基-1-(苯甲基哚-4-基)氧)乙酸甲酷之製法 ---------_-------裝--- (請先閱讀背面之注意事寫本頁) 經濟部智慧財產局員工消費合作社印製 取製法2化合物(2 5克,7 7毫莫耳)溶於17 5毫升二氯甲燒 中,以冰浴冷卻溶液。滴加草醯氣(7.1毫升,8 1毫莫耳), 保持反應溫度在3 5 °C以下。3 0分鐘後,仍看到少量起始 物,因此再添加草醯氣(0.5毫升,6毫莫耳)。3 〇分鐘後, 以175毫升二氣甲烷稀釋反應,添加175毫升水。以7 5毫升 水稀釋氫氧化銨(22毫升,309毫莫耳),於冰浴中冷卻。滴 加冷卻之氨溶液至反應混合物中.,保持反應溫度在6。〇以 下。添加完畢時,反應混合物加溫至3 〇 °C,使所有固體溶 解。冷卻至室溫後’分層,以水洗滌有機層。有機溶液與 1 5克活性碳混合1 5分鐘。混合物經寅式鹽過濾。濾液蒸 發,產生之黃色固體自325毫升甲醇中再結晶,產生標題產 物((2-乙基-1-(苯甲基)_ΐΗ-β哚-4-基)氧)乙酸甲酯之黃色固 體(27.2克,收率89%)。 -36- 訂·- 線·2.39 (m, 5 H), 2.23-2_18 (m, 1 H), 1.18 (t, J = 7.5, 3 H). 13C NMR (CDC13, 75 MHz) ci 185.53, 143.86, 141.41, 139.45, 138.25, 136.15, 129.67, 129.02, 127.71, 125.47, 124.76, 120.10, 102.43, 71.62, 47.14, 21.77, 21.48, 19.92, 19.35, 12.17. TLC Rf 0.32 and 0.26 (1/1 hexane / EtoAc). iH NMR (CDC13, 500 MHz 'Rf 0.26 resonance cannot be resolved) 82 (Mountain J = 7 2, 2 h), 6 33 (s, 1 H), 4.94 (dd, J = 16.9, 23.9, 2 H), 4.01 (dd, J = 4.7, 9.1, 1 H) ° nc nmr (cdci3, all resonances observed) 5 186 98, 186.33, 144.82, 142.03, 140.06, 139.00, 137.58, 136.98, 136.85, 130.42, 130.1 1, 129.70 , 129.65, 129.26, 128.37, 126.61, 126.27, 125.39, 120.91, -35- The scale of the scale is applicable to the Chinese National Standard (CNS) ^ 4 specifications (2 丁 〇_χ 297 meals) ---- 1 --- · ------- Installation—— (Please read the notes on the back to write this page) -ir-VJ · -line. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 04 2 7 A7 __B7__. V. Description of the invention (33) 120.74, 103.04, 102.77, 71.97, 69.72, 61.Q1, 47 78, 47 72 22.11, 21.90, 21.70, 21.30, 21.24, 20.68, 19.97 '19.71 1489 12.84, 12.79. D. ((2-Ethyl-1- (benzylindol-4-yl) oxy) acetic acid methyl chloride production method ---------_------- pack --- ( Please read the notes on the back first to write this page) The method 2 compound (25 g, 7 7 mol) printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs was dissolved in 17 5 ml of dichloromethane, and the ice bath Cool the solution. Add grass gas (7.1 ml, 81 mmol) dropwise and keep the reaction temperature below 35 ° C. After 30 minutes, a small amount of starting material is still visible, so add grass gas (0.5 Ml, 6 mmol). After 30 minutes, the reaction was diluted with 175 ml of digas methane, and 175 ml of water was added. Ammonium hydroxide (22 ml, 309 mmol) was diluted with 75 ml of water in an ice bath. Cool. Add the cooled ammonia solution to the reaction mixture dropwise, keeping the reaction temperature below 6.0. When the addition is complete, warm the reaction mixture to 30 ° C to dissolve all the solids. After cooling to room temperature, 'layering' The organic layer was washed with water. The organic solution was mixed with 15 g of activated carbon for 15 minutes. The mixture was filtered through yin salt. The filtrate was evaporated, and the resulting yellow solid was reconstituted from 325 ml of methanol. Crystals to give the title product ((2-ethyl-1- (benzyl) _fluorene-β-indol-4-yl) oxy) methyl acetate as a yellow solid (27.2 g, yield 89%). ·-Line ·

本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)This paper size applies to China National Standard (CNS) A4 (210 X 297 mm)

Claims (1)

472041 第邰1〇6〇24號專利申請案 会| 中文申請專利範圍修正本(89年2月)品六、申請專利範圍 Γ ^472041 Patent Application No. 〇106〇24 | Chinese Patent Application Amendment (February 89) Product VI. Patent Application Γ ^ 一種製備式I化合物或其醫藥上可接受之鹽或前藥衍生物 之方法Method for preparing compound of formula I or a pharmaceutically acceptable salt or prodrug derivative thereof 其中= R選自.C7-C2Q燒基;Where = R is selected from .C7-C2Q alkyl; (請先聞讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印製 其中: R10選自:鹵素,CrC10烷基.、(^-(:10烷氧基、-S-(CrC10 烷基)及鹵素(crc10)烷基,且t為0至5之整數; R2選自:氫、鹵素、CrC3烷基、C3-C4環烷基、c3-C4環晞 基、-O-OCrC^烷基)、-S-(-CrC2烷基)、芳基、芳氧 基、及HET ; R選自:-CO2H、-SO3H、及-P(0)(0H)2或其鹽或前藥衍 生物;及 本紙張尺度適用中國國家標準(CNS ) Μ規格(210X297公釐) 472041 8 888 ABCD 六、申請專利範圍 R選自·氫,(Crc6)烷基、(Ci_C6)烷氧基、鹵素(C丨· 烷氧基、南素(C2_C0)烷基 '溴、氯、氟、碘 該方法包括下列步驟: 土, a) 由式X化合物 X 其中R8為(crc6)烷基、芳基或HET 與S〇2Cl2鹵化形成式IX化合物 (請先閲讀背面之注意事項再填寫本頁) 〇(Please read the precautions on the back before filling out this page) Printed by the Consumer Cooperatives of the Central Bureau of Standards, Ministry of Economic Affairs, where: R10 is selected from: halogen, CrC10 alkyl., (^-(: 10 alkoxy, -S -(CrC10 alkyl) and halogen (crc10) alkyl, and t is an integer from 0 to 5; R2 is selected from: hydrogen, halogen, CrC3 alkyl, C3-C4 cycloalkyl, c3-C4 cyclofluorenyl,- O-OCrC ^ alkyl), -S-(-CrC2alkyl), aryl, aryloxy, and HET; R is selected from: -CO2H, -SO3H, and -P (0) (0H) 2 or Salt or prodrug derivative; and this paper size applies Chinese National Standard (CNS) M specification (210X297 mm) 472041 8 888 ABCD 6. The scope of patent application R is selected from hydrogen, (Crc6) alkyl, (Ci_C6) alkane Oxygen, halogen (C 丨 · alkoxy, southern (C2_C0) alkyl 'bromine, chlorine, fluorine, iodine. The method includes the following steps: earth, a) from compound X of formula X where R8 is (crc6) alkyl , Aryl or HET and S02Cl2 halogenated to form the compound of formula IX (Please read the precautions on the back before filling this page). '〇 y r Cl IX; 、1T b) 由式IX化合物水解及脫除羧基 IX 〇 〇 Cl 經濟部中央標準局員工消費合作社印裝 形成式VIII化合物 C1 VIII; C) 由式VII化合物 -2- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公羡) 472041 A8 B8 C8 D8 六、申請專利範圍 〇'〇yr Cl IX; 1T b) Hydrolyze and remove carboxyl group IX from the compound of formula IX 〇〇Cl Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy to form the compound of formula VIII C1 VIII; Paper size applies to Chinese National Standard (CNS) A4 specification (210X297 public envy) 472041 A8 B8 C8 D8 6. Scope of patent application R ^ Ο VII 與式VIII化合物進行烷化 C1 〇 A VIII 形成式VI化合物R ^ Ο VII is alkylated with a compound of formula VIII C 1 O A VIII to form a compound of formula VI R VI. (請先閲讀背面之注意事項再填寫本頁) d) 由式VI化合物 〇R VI. (Please read the notes on the back before filling out this page) d) From the compound of formula VI 〇 R 、〇 〇 R' VI 經濟部中央標準局員工消費合作社印製 與式Ι^ΝΗ2於可與水共沸之溶劑存在下 水,形成式V化合物 進行胺化及脫 0R, 〇 〇 R 'VI Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs and formula I ^ NΗ2 in the presence of a solvent capable of azeotroping with water, forming a compound of formula V for amination and deamination 0 R V/ 3- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 472041 A8 B8 C8 D8 0HR V / 3- This paper size applies to Chinese National Standard (CNS) Α4 size (210X297 mm) 472041 A8 B8 C8 D8 0H 六、申請專利範圍 e) 由式V化合物Scope of patent application e) From the compound of formula V R V 與鹼及式RSOX化合物加熱,其中R為-(q-Cd烷基、芳 基或經取代芳基,且X為- (Ci-Ce)烷氧基、i素或 -OCO^CVCe)烷基,氧化形成式IV化合物 R IV; f) 由式IV化合物 (請先閱讀背面之注意事項再填寫本頁) 0HRV is heated with a base and a compound of the formula RSOX, where R is-(q-Cd alkyl, aryl, or substituted aryl, and X is-(Ci-Ce) alkoxy, i prime, or -OCO ^ CVCe) alkane Group, oxidized to form compound IV of formula IV; f) from compound of formula IV (please read the precautions on the back before filling this page) 0H V I 2 R 經濟部中央標準局員工消費合作社印製 與式XCH2R4a烷化劑烷化,其中X為脫離基,且尺43為 -C02R4b、-S03R4b、-P(0)(0R4b)2、或-P(0)(〇R4b)H,其中 R4b為酸保護基團,形成式111化合物 -4 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 472041 A8 B8 C8 D8 六、申請專利範圍VI 2 R Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs and alkylated with the formula XCH2R4a, where X is a radical and the ruler 43 is -C02R4b, -S03R4b, -P (0) (0R4b) 2, or- P (0) (〇R4b) H, in which R4b is an acid-protecting group, forming a compound of formula 111-4 This paper is in accordance with the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 472041 A8 B8 C8 D8 Patent application scope III;。丨( g) 由式III化合物III ;.丨 (g) by compound of formula III R III 與草醯氣及氨反應,形成式II化合物R III reacts with grass gas and ammonia to form a compound of formula II I h) 可視需要水解式II化合物 (請先閱讀背面之注意事項再填寫本頁) *1T 經濟部中央標準局員工消費合作社印製I h) Hydrolyze the compound of formula II if necessary (please read the notes on the back before filling this page) * 1T Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 及 II 形成式I化合物;及 i) 可視需要由式I化合物形:成鹽 5- 本紙張尺度逋用中國國家標準(CNS ) Α4規格(210Χ297公釐) %·. 472041 A8 B8 C8 D8 六、申請專利範圍 2. —種製備式I化合物或其醫藥上可接受之鹽或前藥衍生物 之方法And II to form a compound of formula I; and i) If necessary, the compound of formula I can be formed into a salt: 5- This paper size uses the Chinese National Standard (CNS) A4 specification (210 × 297 mm)% · 472041 A8 B8 C8 D8 Patent application range 2. —A method for preparing a compound of formula I or a pharmaceutically acceptable salt or prodrug derivative thereof 其中= R1選自:C7-C20烷基; (請先閱讀背面之注意事項再填寫本頁)Where = R1 is selected from: C7-C20 alkyl; (Please read the notes on the back before filling this page) 經濟部中央標準局員工消費合作社印製 其中= R10選自:鹵素,CVCh)烷基、(^-(:⑺烷氧基、-SJCt-Cjo 烷基)及鹵素(CrC10)烷基,且t為0至5之整數; R2選自:氫、鹵素、CrC3烷基、C3-C4環烷基、C3-C4環烯 基、烷基)、-S-GCVCz烷基)、芳基、芳氧 基、及HET ; -6 - 本紙張尺度適用中國國家標準(CNS ) A4現格(210X297公釐) 4/2041 A8 B8 C8 D8 申請專利範圍 R選自c〇2H ' -s〇3H、及-Ρ(0)(0Η)2或其鹽或前藥衍 生物;及 R5選氫,(Cl-c6)垸基、(Ci_C6)燒氧基、自素(Ci_c6) ,忧乳基、_素(&lt;:2-(:6)烷基、溴、氯、氟、蛾及芳芙; 該方法包括下列步驟·· 土 e) 由式V化合物Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs where = R10 is selected from: halogen, CVCh) alkyl, (^-(: alkoxy, -SJCt-Cjo alkyl), and halogen (CrC10) alkyl, and t Is an integer from 0 to 5; R2 is selected from: hydrogen, halogen, CrC3 alkyl, C3-C4 cycloalkyl, C3-C4 cycloalkenyl, alkyl), -S-GCVCz alkyl), aryl, aryloxy Base and HET; -6-This paper size is applicable to Chinese National Standard (CNS) A4 now (210X297 mm) 4/2041 A8 B8 C8 D8 The scope of patent application R is selected from c〇2H'-s〇3H, and- P (0) (0Η) 2 or a salt or prodrug derivative thereof; and R5 hydrogen selection, (Cl-c6) fluorenyl, (Ci_C6) carboxy, Ci_c6, lactol, and _ &lt;: 2-(: 6) alkyl, bromine, chlorine, fluorine, moth, and fangfu; the method includes the following steps: · e) from a compound of formula V V R 與鹼及式RSOX化合物 具中R為-(CVC0烷基、 基或經取代芳基且X為_(Ci_C6)烷氧基、由素 -〇C〇2(CrC6)烷基,氧化形成式IV化合物 OHVR and the base and the compound of formula RSOX in which R is-(CVC0 alkyl, aryl or substituted aryl, and X is _ (Ci_C6) alkoxy, and is oxidized to form a formula -0 CO 2 (CrC 6) alkyl IV compound OH • /. V I 2 R 經濟部中央標準局員工消費合作社印製• /. V I 2 R Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (請先閲讀背面之注意事項再填寫本頁)(Please read the notes on the back before filling this page) 472041 OCH R4a472041 OCH R4a R' A8 B8 C8 D8 六、申請專利範圍 與式XCH2R4a烷化劑烷化,其中X為脫離基,且尺“為 -C02R4b、-S03R4b、-P(0)(0R4b)2、或-P(0)(0R4b)H,其中 R4b為酸保護基團,形成式III化合物 III, g) 由式III化合物 (請先閱讀背面之注意事項再填寫本頁) OCH R1'R 'A8 B8 C8 D8 VI. Patent application scope and alkylation of alkylating agent of formula XCH2R4a, where X is a leaving group, and the rule "is -C02R4b, -S03R4b, -P (0) (0R4b) 2, or -P ( 0) (0R4b) H, where R4b is an acid-protecting group to form a compound III of formula III, g) From a compound of formula III (please read the precautions on the back before filling this page) OCH R1 ' R I I I 與草醯氣及氨反應,形成式II化合物R I I I reacts with grass gas and ammonia to form a compound of formula II 經濟部中央標準局員工消費合作社印製 h) 可視需要水解式II化合物 -8- 本紙浪尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 472041 A8 B8 C8 D8 I I 六、申請專利範圍Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs h) Hydrolyzed compound of formula II as required -8- The standard of this paper is applicable to China National Standard (CNS) A4 (210X297 mm) 472041 A8 B8 C8 D8 I I 6. Scope of patent application 2 形成式I化合物;及 i) 可視需要由式I化合物形成鹽。 3 . —種製備式I化合物或其醫藥上可接受之鹽或前藥衍生物 之方法2 forming a compound of formula I; and i) optionally forming a salt from a compound of formula I. 3. A method for preparing a compound of formula I or a pharmaceutically acceptable salt or prodrug derivative thereof 其中: R1選自:C7-C2〇烷基; (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製Among them: R1 is selected from: C7-C2O alkyl; (Please read the notes on the back before filling out this page) Printed by the Staff Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs -9- 本紙張尺度適用中國國家榇準(CNS ) A4規格(210X297公釐) -0-(-CrC2烷基)、-S + CVC〗烷基)、芳基、 h=- 方孔 藥衍 472041 A8 B8 C8 D8 申請專利範圍 R10選自:_ 素,CrC10炫基、Crc10垸氧基、 烷基)及鹵素(CpC丨〇)烷基,且t為〇至5之整數;1 10 R2選自:氫、鹵素、CrC3烷基、〇:3-(:4環烷基、Γ _ 基、a / 广 ^ …^ _ 3 埽 基、及HET ; R4選自:-C02H、-S03H、及-p(o)(〇h)2或其鹽戋 ^ 生物;及 、- R5選自:氫’(crc6)烷基、(Crc6)烷氧基、自 規氧基、函素(C2-C6)燒基、漠、氯、氟、碼及—丨其匕) 該方法包括下列步驟: 方土 a) 由式X化合物 (請先閲讀背面之注意事項再填寫本頁) R\ 0 0、〇从 訂 X ^w. 其中R8為(CrC6)烷基、芳基或HET ; 與S02C12鹵化形成式IX化合物: 0 0-9- This paper size is applicable to China National Standard (CNS) A4 (210X297 mm) -0-(-CrC2 alkyl), -S + CVC〗 alkyl), aryl, h =- 472041 A8 B8 C8 D8 The scope of patent application R10 is selected from the group consisting of: _ element, CrC10 xyl, Crc10 alkoxy, alkyl) and halogen (CpC 丨 〇) alkyl, and t is an integer from 0 to 5; 1 10 R2 selected From: hydrogen, halogen, CrC3 alkyl group, 0: 3-(: 4-cycloalkyl group, Γ_ group, a / b ^^^ 3 fluorenyl group, and HET; R4 is selected from: -C02H, -S03H, and -p (o) (〇h) 2 or a salt thereof; and, -R5 is selected from the group consisting of: hydrogen '(crc6) alkyl, (Crc6) alkoxy, self-defined oxygen, and halo (C2-C6 The method includes the following steps: Clay a) From the compound of formula X (please read the precautions on the back before filling this page) R \ 0 0 、 〇 X ^ w. Where R8 is (CrC6) alkyl, aryl, or HET; halogenated with S02C12 to form a compound of formula IX: 0 0 經濟部中央標準局員工消費合作社印製 b) 由式IX化合物水解及脫除羧基 -10- 472041 A8 B8 C8 D8 六、申請專利範圍 〇 〇Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs b) Hydrolysis and removal of carboxyl groups from compounds of formula IX -10- 472041 A8 B8 C8 D8 6. Scope of patent application 〇 〇 〇 Τ ΓΤ C1 IX 形成式VIII化合物 C1 乂c) 由式VII化合物 VIII,〇 ΓΓΤ C1 IX forms a compound of formula VIII C1 乂 c) from compound VIII of formula VII, VII 與式VIII化合物進行烷化 〇 C1,形成式VI化合物 R VIII (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局眞工消費合作社印製 〇VII is alkylated with a compound of formula VIII 〇 C1 to form a compound of formula VI R VIII (Please read the notes on the back before filling out this page) R d) 由式VI化合物 VI, 11 - 本紙張尺度適用中國國家梂準(CNS ) A4規格(210X297公釐) 472041 A8 B8 C8 D8 申請專利範圍 0R d) Compound VI of Formula VI, 11-This paper size applies to China National Standard (CNS) A4 (210X297 mm) 472041 A8 B8 C8 D8 Patent Application Range 0 R VI 與式Ι^ΝΗ2於可與水共沸之溶劑存在下 水,形成式V化合物 進行胺化及脫 R ) 由式V化合物 〇A— N R ‘ R1 V; 〇R VI and formula I ^ NΗ2 in the presence of a solvent capable of azeotroping with water, water to form a compound of formula V for amination and de-R) From the compound of formula V 〇A- N R ′ R1 V; 〇 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 與鹼及式RSOX化合物加熱,其中R為烷基、芳 基、或經取代芳基,且X為-(C i - C 6)烷氧基、齒素或 -OC〇2(CrC6)烷基,氧化形成式V1化合物 〇(Please read the notes on the back before filling this page) Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs and heated with alkali and formula RSOX compounds, where R is alkyl, aryl, or substituted aryl, and X is- (C i-C 6) alkoxy, dentin, or -OC〇2 (CrC6) alkyl, which is oxidized to form a compound of formula V1. R V1; e1) 加熱式V1化合物,形成式IV化合物 12- 本紙張尺度逋用中國國家標準(CNS ) A4規格(210 X 297公釐) 472041 A8 B8 C8 D8 六、申請專利範圍R V1; e1) The compound of formula V1 is heated to form the compound of formula IV. 12- This paper uses Chinese National Standard (CNS) A4 specifications (210 X 297 mm) 472041 A8 B8 C8 D8. 6. Scope of patent application ./. V I 2 R e π)由式IV化合物先經鹼及與水互溶之溶劑處理 後以有機溶劑萃取純化; f) 由式IV化合物./. V I 2 R e π) The compound of formula IV is first treated with a base and a solvent miscible with water, and then extracted and purified with an organic solvent; f) From the compound of formula IV 經式X C Η 2 R4 a烷化劑烷化,其中X為脫離基且R4 a為 -C02R4b、-S03R4b、-P(0)(0R4b)2 或-P(0)(0R4b)H,其中 R4b為酸保護基,形成式111化合物 (請先閲讀背面之注意事項再填寫本頁)Alkylated with an alkylating agent of formula XC Η 2 R4 a, where X is a leaving group and R4 a is -C02R4b, -S03R4b, -P (0) (0R4b) 2 or -P (0) (0R4b) H, where R4b It is an acid protecting group to form a compound of formula 111 (please read the precautions on the back before filling this page) R 經濟部中央標準局舅工消費合作社印製 III, g) 由式III化合物 OCH R Q- NIR R 3 本紙張尺度逋用中國國家揉準(CNS ) A4規格(210X297公釐) 472041 A8 B8 C8 D8 六、申請專利範圍 與草醯氯及氨反應,形成式II化合物R Printed by Central Government Bureau of Standards, Ministry of Economics, Consumer Goods Cooperative, g) OCH R Q- NIR R 3 Compound of formula III This paper is in Chinese standard (CNS) A4 size (210X297 mm) 472041 A8 B8 C8 D8 VI. The scope of the patent application reacts with grasshopper chlorine and ammonia to form a compound of formula II h ) 可视需要水解式11化合物 (請先閱讀背面之注意事項再填寫本頁)h) If necessary, hydrolyze the compound of formula 11 (please read the precautions on the back before filling this page) R II 經濟部中央標準局舅工消費合作社印製 形成式I化合物;及 i) 可視需要由式I化合物形成鹽。 4 . 一種製備式I化合物或其醫藥上可接受之鹽或前藥衍生物 之方法R II Printed by the Central Standards Bureau, Ministry of Economic Affairs, Masonry Consumer Cooperative, to form a compound of formula I; and i) If necessary, a salt of a compound of formula I can be formed. 4. A method for preparing a compound of formula I or a pharmaceutically acceptable salt or prodrug derivative thereof 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) A8 B8 C8 D8 申請專利範圍 其中: R1選自:c7-c2G烷基 —(CH)This paper size applies to Chinese National Standard (CNS) A4 specification (210X297 mm) A8 B8 C8 D8 Patent application scope Among them: R1 is selected from: c7-c2G alkyl — (CH) •CH- 與• CH- and 經濟部t央標準局員工消費合作社印製 其中: R 0選自.函素’ Cl-Cio燒基、CrC10燒氧基、-s-(crc10 2健基)及齒素(Cl_cio)烷基,且t為0至5之整數; R選自·氫、鹵素、ci_C3烷基、C3-C4環烷基、C3-C4環晞 基、-0-(-crc2烷基)、_s_(_Ci_c2烷基)、芳基、芳氧 基、及HET ; R4i! 1: _c〇2H、_s〇3H、及-p(o)(oh)2或其鹽或前藥衍 生物;及 R5選自:氫,(crc6)烷基、(c c ) 烷鱼其、南丰( 1 6)k虱基、函素(CrC6) 烷虱基' 1¾素(c2-c6)烷基、溴 . 該方法包括下列步騾: 虱軋、碘及芳基; e) 由式V化合物 -15- 表紙張尺度適用中( 210 X 2_97^iT ITilAw. (請先閱讀背面之注意事項再填寫本頁) 472041 A8 B8 C8 D8 IX V 申請專利範圍Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs, where: R 0 is selected from the group consisting of Cl-Cio alkyl, CrC10 alkyl, -s- (crc10 2 alkyl), and Cl_cio alkyl. And t is an integer from 0 to 5; R is selected from hydrogen, halogen, ci_C3 alkyl, C3-C4 cycloalkyl, C3-C4 cyclofluorenyl, -0-(-crc2 alkyl), _s _ (_ Ci_c2 alkyl ), Aryl, aryloxy, and HET; R4i! 1: _co2H, _s〇3H, and -p (o) (oh) 2 or a salt or prodrug derivative thereof; and R5 is selected from: hydrogen, (Crc6) alkyl, (cc) alkanochi, Nanfeng (16) kyl, Cr (C6) alkynyl '1¾ (c2-c6) alkyl, bromine. The method includes the following steps: : Lice rolling, iodine and aryl; e) Compounds of formula V- 15- Applicable paper size (210 X 2_97 ^ iT ITilAw. (Please read the precautions on the back before filling this page) 472041 A8 B8 C8 D8 IX V Scope of Patent Application 與鹼及式RSOX化合物加熱,其中R為-(CrCd烷基、芳 基、或經取代芳基,且X為- (Ci-Cj烷氧基、鹵素或 -OCOXCi-Cd烷基,氧化形成式V1化合物 RHeating with a base and a compound of formula RSOX, where R is-(CrCd alkyl, aryl, or substituted aryl, and X is-(Ci-Cj alkoxy, halogen, or -OCOXCi-Cd alkyl, and oxidizes to form the formula V1 Compound R 2 -R e1) 加熱式V1成份,形成式IV化合物 e u)由式IV化合物先經鹼於可與水互溶之溶劑中處 理,再以有機溶劑萃取純化; (請先閱讀背面之注意事項再填寫本頁) OH2 -R e1) The compound of formula V1 is heated to form a compound of formula IV eu) The compound of formula IV is first treated with a base in a solvent miscible with water, and then extracted and purified with an organic solvent; (Please read the notes on the back before filling (This page) OH 經濟部中央標準局員工消費合作社印製 κ IV; f) 由式IV化合物Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs κ IV; f) from compounds of formula IV 2 V 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 4720412 V This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) 472041 R' R A8 B8 C8 D8 申請專利範圍 經式X C H 2 R4 a烷化劑烷化,其中X為脫離基且R4 a為 -C02R4b、-S03R4b、-P(0)(0R4b)2 或-P(〇)(〇R4b)H,其中 R4b為酸保護基,形成式111化合物 III, g) 由式III化合物 (請先閱讀背面之注意事項再填寫本頁) OCH RR 'R A8 B8 C8 D8 The scope of the patent application is alkylated with an alkylating agent of formula XCH 2 R4 a, where X is a leaving group and R4 a is -C02R4b, -S03R4b, -P (0) (0R4b) 2 or -P ( 〇) (〇R4b) H, where R4b is an acid protecting group to form compound III of formula 111, g) From compound of formula III (please read the precautions on the back before filling this page) OCH R 經濟部中央標準局員工消費合作社印製 與草醯氯及氨反應,形成式π化合物Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. h) 可視需要水解式11化合物 -17 本紙浪尺度逋用中國國家梯準(CNS ) A4規格(210X297公釐) 472041h) Hydrolyze the compound of formula 11 if necessary -17 This paper uses the Chinese National Standard (CNS) A4 size (210X297 mm) 472041 I I 衂濟部中央蒙f 5費合作社 市成式丨化合物;及 0可視需要由式1化合物形成鹽》 5 .根據中請專利範園第!至4項中任二工、 酸化試劑係選自對甲苯酿基亞績酸c,其中心 磺酸甲酯。 、&amp;衧或對甲苯j 6. 根據申請專利範圍第丨至4项中任—項、、 ((3-(2-胺基-I,2-二氧乙基)_2 '方法,其係製名 4-基)氧)乙酸。 )2乙基+(苯甲基朵 7. 根據申請專利範圍第1至4項中任—项、、 中,驗係選自:甲醇卸、甲醇納、:C醇:驟(e 8. 根據申請專利範圍第7项之方法,其中驗 醇广 9. 根據申請專利範圍第8項之方 [·〒。 之0.75至H)當量。 其中驗《含量為起始物 H)·根據申請專利範圍第9項之方法,其中驗為 11. 根據申請專利範圍第10項之方 了。 苯。 π 丹肀有機溶劑為甲 12. 根料請專利範圍第3或4項之方法,其t步驟 與水互溶之溶劑選自:T醇、丙g同及異丙醇,驗 自··氫氧化鋰、氫氧化鉀及氫氧化鈉。 、、 13. 根據t請專利範圍第12项之方法,#中與水互溶I I, the Ministry of Economic Affairs, Central Mongolia, F5, and Co., Ltd. to formulate a compound; and 0 to form a salt from a compound of formula 1 if necessary. 5) According to the patent application, please refer to the patent! Any of the 4 to 4 items of acidification reagents is selected from p-toluenyl sulfonic acid c, and its center is methyl sulfonate. , &Amp; 衧 or p-toluene j 6. According to any one of the items 1 to 4 of the scope of patent application, ((3- (2-amino-I, 2-dioxyethyl) _2 'method, which is The name 4-yl) oxy) acetic acid. ) 2 ethyl + (benzyl flower 7. According to any of the items 1 to 4 in the scope of the application for patents-items, ,, and, the test system is selected from the group consisting of: methanol unloading, sodium methoxide, C alcohol: sudden (e 8. according to The method of applying for item 7 of the patent scope, which includes the alcohol test 9. According to the method of the application of the item 8 of the scope [· 〒. Of 0.75 to H) equivalent. Among them, the content of "starting substance H) · According to the scope of patent application The method of item 9, of which the test is 11. According to the method of item 10 of the scope of patent application. benzene. The organic solvent of tannin is M12. The method of claim 3 or 4 of the patent scope, the solvent of t step and water miscibility is selected from the group consisting of: T alcohol, propyl g and isopropanol. Lithium, potassium hydroxide and sodium hydroxide. 、 13. According to the method of the 12th patent scope, # 中 is soluble in water 472041 A8 Β8 C8 D8 六、申請專利範圍 為甲醇,且鹼為氫氧化鈉。 14. 根據申請專利範圍第1 3項之方法,其中鹼之濃度為0.5N 至5N。 15. 根據申請專利範圍第1 4項之方法,其中鹼之濃度為1 .5N 至 2.5N。 16. 根據申請專利範圍第1 5項之方法,其中鹼之濃度為2N。 17. 根據申請專利範圍第1 6項之方法,其中pH為10.5至 11.5。 18. 根據申請專利範圍第1 7項之方法,其中pH為1 1。 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 -19- 本紙張尺度逋用中國國家標準(CNS ) A4说格(210X297公釐)472041 A8 B8 C8 D8 6. The scope of patent application is methanol, and the base is sodium hydroxide. 14. The method according to item 13 of the scope of patent application, wherein the alkali concentration is 0.5N to 5N. 15. The method according to item 14 of the scope of patent application, wherein the alkali concentration is 1.5N to 2.5N. 16. The method according to item 15 of the scope of patent application, wherein the alkali concentration is 2N. 17. The method according to item 16 of the patent application scope, wherein the pH is 10.5 to 11.5. 18. The method according to item 17 of the scope of patent application, wherein the pH is 11. (Please read the notes on the back before filling out this page) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs -19- This paper uses Chinese National Standard (CNS) A4 format (210X297 mm)
TW088106024A 1998-10-09 1999-04-15 Process for preparing 4-substituted-1H-indole-3-glyoxamides TW472041B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10360498P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
TW472041B true TW472041B (en) 2002-01-11

Family

ID=22296053

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088106024A TW472041B (en) 1998-10-09 1999-04-15 Process for preparing 4-substituted-1H-indole-3-glyoxamides

Country Status (11)

Country Link
EP (1) EP1119549A4 (en)
JP (1) JP2002527421A (en)
AR (1) AR015766A1 (en)
AU (1) AU3564499A (en)
CA (1) CA2347718A1 (en)
CO (1) CO5021230A1 (en)
DZ (1) DZ2771A1 (en)
PE (1) PE20000429A1 (en)
SV (1) SV1999000042A (en)
TW (1) TW472041B (en)
WO (1) WO2000021929A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032769A (en) * 1983-08-02 1985-02-19 Sagami Chem Res Center Preparation of 4-hydroxyindole derivative
UA47387C2 (en) * 1994-04-01 2002-07-15 Елі Ліллі Енд Компані 1H-INDOLE-3-GLYOXYLAMIDES AS INHIBITORS OF sPLA2 AND PHARMACEUTICAL COMPOSITION ON THEIR BASIS
EP0987250A4 (en) * 1997-02-20 2000-12-06 Shionogi & Co Indole dicarboxylic acid derivatives

Also Published As

Publication number Publication date
WO2000021929A1 (en) 2000-04-20
EP1119549A4 (en) 2003-01-29
EP1119549A1 (en) 2001-08-01
DZ2771A1 (en) 2003-12-01
PE20000429A1 (en) 2000-05-23
SV1999000042A (en) 2000-04-11
AR015766A1 (en) 2001-05-16
CO5021230A1 (en) 2001-03-27
JP2002527421A (en) 2002-08-27
AU3564499A (en) 2000-05-01
CA2347718A1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
HU220221B (en) 1h-indole-3-acetic acid hydrazide derivatives, pharmaceutical compositions comprising them and process for producing thereof
BRPI0808440A2 (en) PPAR ACTIVE COMPOUNDS
HU227913B1 (en) Phenyl heterocycles as cyclooxygenase-2 inhibitors
US20080255111A1 (en) Tissue Factor Production Inhibitor
WO2010150837A1 (en) Indoline derivative
TWI289562B (en) Process for the preparation of sulphonamide-substituted imidazotriazinones
TW472041B (en) Process for preparing 4-substituted-1H-indole-3-glyoxamides
TW455581B (en) Process for preparing 4-substituted-1H-indole-3-glyoxamides
WO2008001959A1 (en) Novel 6-5 bicycic heterocyclic derivative and medical use thereof
US6265591B1 (en) Process for preparing 4-substituted-1h-indole-3-glyoxamides
JPS6159305B2 (en)
Hojati et al. New Mothod for Synthesis of Indole Derivatives via Zirconium (IV) Chloride Catalyst
US6380397B1 (en) Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6617460B1 (en) Process for preparing toluenesulfinates
US6570023B1 (en) Process for preparing toluenesulfinates
JPS5927869A (en) Preparation of 4-oxo-4,5,6,7-tetrahydroindole
MXPA00009955A (en) Process for preparing 4-substituted-1h-indole-3-glyoxamides
JP2012516327A (en) Novel process for the production of carboxy-containing pyrazole amide compounds
TW201718492A (en) Method for manufacturing 4-(4-formylthiazolyl)piperidine compound
CZ20003824A3 (en) Process for preparing 4-substituted-1H-indole-3-glyoxamides
MXPA99011973A (en) Process for preparing 4-substituted-1h-indole-3-glyoxamides